Tracking the In Vivo Dynamics of Antigenic Variation in the African Trypanosome by Mugnier, Monica R
Rockefeller University
Digital Commons @ RU
Student Theses and Dissertations
2016
Tracking the In Vivo Dynamics of Antigenic
Variation in the African Trypanosome
Monica R. Mugnier
Follow this and additional works at: http://digitalcommons.rockefeller.edu/
student_theses_and_dissertations
Part of the Life Sciences Commons
This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and
Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact mcsweej@mail.rockefeller.edu.
Recommended Citation
Mugnier, Monica R., "Tracking the In Vivo Dynamics of Antigenic Variation in the African Trypanosome" (2016). Student Theses and
Dissertations. Paper 317.
TRACKING THE IN VIVO DYNAMICS OF ANTIGENIC 
VARIATION IN THE AFRICAN TRYPANOSOME 
A Thesis Presented to the Faculty of 
The Rockefeller University 
in Partial Fulfillment of the Requirements for 
the degree of Doctor of Philosophy 
by 
Monica R. Mugnier 
June 2016 
©  Copyright by Monica R. Mugnier 2016 
TRACKING THE IN VIVO DYNAMICS OF ANTIGENIC 
VARIATION IN THE AFRICAN TRYPANOSOME 
Monica Mugnier, Ph.D. 
The Rockefeller University 2016 
Trypanosoma brucei, a causative agent of African sleeping sickness in humans 
and nagana in animals, constantly changes its dense variant surface glycoprotein (VSG) 
coat to avoid elimination by the immune system of its mammalian host, using an 
extensive repertoire of dedicated genes. Although this process, referred to as antigenic 
variation, is the major mechanism of pathogenesis for T. brucei, the dynamics of VSG 
expression in T. brucei during an infection are poorly understood.  
In this thesis, I describe the development of VSG-seq, a method for quantitatively 
examining the diversity of expressed VSGs in any population of trypanosomes. Using 
VSG-seq, I monitored VSG expression dynamics in vivo during both acute and chronic 
mouse infections. My experiments revealed unexpected diversity within parasite 
populations, and the expression of as much as one-third of the functional genomic VSG 
repertoire after only one month of infection.  
In addition to suggesting that the host-pathogen interaction in T. brucei infection 
is substantially more dynamic and nuanced than previously expected, this observed 
diversity highlighted the importance of the mechanisms by which T. brucei diversifies its 
genome-encoded VSG repertoire. During infection, the parasite can form mosaic VSGs, 
novel variants that arise through recombination events within the parasite genome during 
infection.  Though these novel variants had been identified previously, little was known 
about the mechanisms by which they form. VSG-seq facilitated the identification of 
mosaic VSGs during the infection, which allowed me to track their formation over time. 
My results provide the first temporal data on the formation of these variants and suggest 
that mosaic VSGs likely form at sites of VSG transcription.  
VSG-seq, which is based on the de novo assembly of VSGs, obviates the 
requirement for a reference genome for the analysis of expressed VSG populations. This 
allows the method to be used for the high-resolution study of VSG expression in any 
strain of T. brucei, whether in the lab or in the field. To this end, I have applied VSG-seq 
to samples grown in vitro, parasites isolated from natural infections, and extravascular 
parasites occupying various tissues in vivo. These extensions of the method reveal new 
aspects of T. brucei biology and demonstrate the potential of high-throughput approaches 
for studying antigenic variation, both in trypanosomes and in any pathogen that uses 
antigenic variation as a means of immune evasion. 
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 CHAPTER 1.  Introduction 
 
1.1 Trypanosoma brucei 
African sleeping sickness, or human African trypanosomiasis (HAT), is a vector-
borne disease affecting sub-Saharan Africa. It is fatal if left untreated, most existing 
drugs are extremely toxic, and the economic burden of sleeping sickness, along with its 
zoonotic counterpart, nagana, is estimated to be at least 1.5 billion USD per year1. The 
economic burden of this disease is due largely to the animal infection, which commonly 
affects livestock and can be devastating to endemic areas. In fact, there are probably only 
approximately 20,000 cases of HAT per year2. However, underreporting is a problem in 
the poor rural areas typically affected by HAT, so estimating its prevalence can be 
difficult. Nevertheless, the diseases caused by African trypanosomes represent a major 
barrier to economic development in affected regions. 
The causative agents of sleeping sickness and nagana are a group of protozoan 
parasites known as the African trypanosomes, of which there are two human-infective 
subspecies: Trypanosoma brucei gambiense, which is found in west and central Africa 
and causes a chronic infection lasting months to years, and T. brucei rhodesiense, which 
is found in east Africa and causes an acute form of the disease lasting weeks to months. 
Humans are resistant to T. brucei brucei as well as a number of other species of 
Trypanosoma, meaning that only animals are infected by these parasites. T. brucei is 
limited geographically to the range of its vector, the tsetse (Glossina sp.), but two African 
trypanosome species, T. evansi and T. equiperdum, which are actually probably 
subspecies of T. brucei3, have evolved new modes of transmission, expanding their range 
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beyond sub-Saharan Africa into Asia and South America. Thus, the range of the African 
trypanosomes and the diseases they cause is large and has the potential to expand. Of all 
of the African trypanosomes, however, T. brucei is the most commonly studied in the 
laboratory and will be the focus of this thesis.  
T. brucei’s entirely extracellular life cycle (Figure 1.1) begins when its vector, the 
tsetse, takes a blood meal from a mammal, transferring metacyclic stage parasites to a 
new mammalian host. These metacyclic forms move from the skin to the bloodstream 
where they transform into long slender bloodstream form parasites. The long slender 
forms divide quickly. As their density increases, they undergo quorum sensing and some 
of the long slender population transforms into non-dividing short stumpy bloodstream 
form parasites, which are primed for transmission back to the fly4,5.  
When a fly bites an infected mammal, these short stumpy trypanosomes are taken 
up and move to the midgut of the fly, where they transform into procyclic form parasites. 
The procyclic forms then move to the fly’s salivary glands, where they further develop 
into epimastigote form parasites which can undergo meiosis, allowing for genetic 
exchange between parasites6,7. The epimastigotes divide for some time in the salivary 
gland before finally becoming metacyclics once again. These parasites can then be 
transmitted to a new host at the fly’s next blood meal. 
During a mammalian infection, long slender and short stumpy trypanosomes 
reside both in the blood and in tissues8 but appear to always live extracellularly. In the 
early stages of infection, patients experience non-specific symptoms such as fever and 
headaches. Eventually, parasites cross the blood-brain barrier and enter the central 
nervous system, though the timing of this transit can vary9,10. This infection of the brain 
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and cerebrospinal fluid defines late-stage infection, and results in severe neuropathology, 
including the disturbance of the circadian rhythm that gives sleeping sickness its name11. 
The drugs required to treat this stage of infection are difficult to administer and 
frequently toxic12. Although prevention of African trypanosomiasis would be ideal, there 
is little hope for a vaccine against T. brucei13,14. One major reason why a vaccine proves 
unlikely is T. brucei’s capacity for antigenic variation, the parasite’s primary mechanism 
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1.2 The variant surface glycoprotein and antigenic variation 
 In 1909, Ross and Thomson applied a new method for counting parasites to the 
blood samples of a patient infected with T. b. gambiense. Their methodical counting 
revealed the periodic peaks and valleys in parasitemia characteristic of T. brucei 
infections15(Figure 1.2), and they and others hypothesized that these waves resulted from 
some kind of habituation to host antibody16. Their guess was not too far off. Decades 
later, the antigenic component of T. brucei responsible for the waves of parasitemia 
during infection was identified as variant surface glycoprotein (VSG)17, and these waves, 
we now understand, are the result of a sort of habituation: T. brucei periodically 
“switches” an antigenic VSG coat, allowing the parasite to escape recognition by host 
antibody.  
 
Figure 1.2. Waves of parasitemia during infection. 
Image adapted from Ross and Thomson, 1910. 
 
VSG, a GPI-anchored glycoprotein, is extremely densely packed on the cell 
surface of metacyclic and bloodstream form parasites18, comprising ~95% of the surface 
proteome19 with approximately 107 identical copies of the protein covering the 
parasite17,20. Due to its abundance, VSG is effectively the only protein “seen” by the host 
immune system. Though the host may mount a response to other trypanosome proteins, 












no other protein can elicit a significant or protective immune response21,22. Therefore, 
changing the VSG coat renders a parasite temporarily invisible to the host, prolonging 
infection. 
Each VSG is composed of a relatively conserved membrane-proximal C-terminal 
domain and a more variable N-terminal domain (Figure 1.3). Only two VSG crystal 
structures exist, and these structures only contain VSG N-termini23,24. Interestingly, the 
structures are superimposable despite only 16% sequence identity24. Analysis of the 
sequence of VSG-encoding genes has identified conserved cysteine residues that may 
play a role in maintaining VSG structure while allowing for such significant sequence 
divergence25. 
Figure 1.3. The VSG coat.  
The Variant Surface Glycoprotein (VSG) densely coats the parasite membrane, as shown 
by electron micrograph (courtesy of George A.M. Cross) displayed in. 10 million VSG 
molecules pack on the surface of the parasite cell (image courtesy of Markus Engstler). 
The parasite takes advantage of its set of structurally similar but antigenically 
diverse VSGs during antigenic variation, the mechanism by which T. brucei changes its 
VSG coat to avoid recognition by the host immune system. Throughout infection, the 
parasite turns on and off expression of individual VSG-encoding genes, from a genomic 
repertoire of ~2000 different genes26,27. As the host immune system recognizes and clears 
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already changed their VSG coat, turning on a new, and likely antigenically distinct, VSG. 
These “switchers” will eventually be recognized by the immune system, but not before 
another set of parasites has turned on another VSG and escaped immune clearance.  
The process of antigenic variation is common to many pathogens, including 
viruses28, bacteria29, and other protozoa30 such as the malaria parasite Plasmodium 
falciparum31. T. brucei, then, can be thought of as a tractable model for an important 
process common to many organisms relevant to public health. 
 
1.3 VSG expression 
 In bloodstream form parasites, VSGs are expressed from one of ~15 telomeric 
bloodstream expression sites (BESs)32(Figure 1.4A). Only one BES is ever transcribed at 
a time, though the mechanisms controlling this monoallelic expression are not well 
understood. Each BES is made up of a promoter, a collection of expression site 
associated genes (ESAGs), a 70-bp repeat sequence, and a VSG. The number and identity 
of ESAGs can vary among sites, and it is not clear whether these genes play a role in 
antigenic variation; many are also expressed from other loci within the genome and 
during other life cycle stages33,34. The 70-bp repeat adjacent to the VSG can vary in length 
between BESs, and the sequence is speculated to play a role in antigenic variation by 
allowing VSG switching to diverse genomic donor sequences35-38. 
The entire BES, from just downstream of the promoter39 through the VSG, is 
polycistronically transcribed by RNA Polymerase I (Pol I)40. This polymerase is 
exclusively responsible for transcription of ribosomal RNA in other organisms, and its 
role in VSG expression may be due to the high level of expression required to produce 
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sufficient VSG to cover T. brucei’s surface. This long Pol I-transcribed unit is then 
processed into individual transcripts and, as is the case for all T. brucei mRNAs, a 5ʹ 
spliced-leader sequence is trans-spliced onto each gene, including the VSG41(Figure 
1.4B). Though VSG sequences are quite divergent from one another at the DNA level, 
they all contain a conserved 14 base pair (bp) sequence in their 3ʹ untranslated region 
(UTR)42. This sequence may play a role in maintaining monoallelic expression of VSG, 




Figure 1.4. VSG expression.  
(A) Schematic of a BES. (B) Schematic of a mature VSG mRNA. 
 
 
Though not the focus of this thesis, metacyclic VSGs are expressed from a 
specialized expression site in metacyclic form parasites43,44. This site is also telomeric, 
but it lacks ESAGS and the 70-bp repeat sequence. Metacyclic expression sites have a 
promoter sequence distinct from that of bloodstream forms26,45,46. 
 
VSG
ESAGs P 70 bp
A
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1.4 VSG switching 
 There are two broad mechanisms by which T. brucei switches VSG expression. 
The first mechanism is transcriptional, or in situ, switching, during which transcription at 
one BES is turned off and transcription at a second BES is turned on47 (Figure 1.5A). It is 
not clear how an in situ switch is initiated. The second mechanism is recombination-
based switching. This can occurs in two ways: duplicative gene conversion (GC) and 
telomere exchange (TE). Telomere exchange occurs through a homologous 
recombination event in which telomere ends are swapped between two chromosomes, 
resulting in a new VSG in the active BES, but retaining the previously active 
VSG48(Figure 1.5B). GC, on the other hand, occurs though a homologous recombination 
event in which a VSG located in a distant site is copied into the active BES. This results 
in the loss of the previously expressed VSG and duplication of the donor VSG sequence 
(Figure 1.5C). This type of switch can be initiated by a DNA double-strand break 
(DSB)49,50 within the active BES, which is then repaired by gene conversion. A number 
of genes known to be involved in homologous recombination in eukaryotes have been 
implicated in this process51,52. While it is thought that recombinatorial switching results 
from naturally occurring DSBs, and that subtelomeric fragility may play a role in the 
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Figure 1.5. Mechanisms of VSG switching.  
T. brucei can switch expression to an antigenically distinct VSG by recombinatorial (top, 
GC and TE) or transcriptional (bottom) switching.  
 
1.5 The genomic VSG repertoire 
 GC based switching, in particular, is extremely important because it allows access 
to the extensive genomic repertoire of VSGs. The key to antigenic variation is the extent 
of this repertoire: recent work sequencing the “VSGnome” of the T. brucei Lister 427 
strain revealed more than 2000 different VSG-encoding genes26. The telomeric BESs 
contain one set of VSGs, but these only represent a small fraction of the repertoire.  The 
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rest of the VSG archive can be found within intra-chromosomal arrays27,55 or in the 
minichromosomes (MCs). MCs are small 30-150kb chromosomes consisting only of VSG 
sequences, a 177-bp repeat sequence, and telomeres56. The enrichment for VSG within 
MCs suggest these tiny chromosomes play a role in antigenic variation, but this role has 
not yet been elucidated. Interesting, the majority of MC VSGs are complete VSGs that 
should produce a full-length and functional VSG26. This is in contrast to the rest of the 
VSG archive, which is primarily composed of incomplete VSGs or VSG pseudogenes. In 
fact, studies of two strains of T. brucei, the Lister 427 strain and the TREU927 genome 
strain, show >80% of genomic VSG sequences are incomplete or pseudogenous26,57.  
 
Figure 1.6. The genomic VSG archive.  
The extensive repertoire of VSG genes is located in various sites throughout the genome. 
Around 15 VSGs are associated with expression sites, where they are transcribed with a 
cohort of Expression Site Associated Genes (ESAGs). Expression sites also contain 
repetitive 70bp repeat elements. Around 100 VSGs are located on ~100 
minichromosomes. Finally, a large number of VSGs are located in chromosome-internal 
regions, where they are often found in combination with ESAGs and repetitive elements. 
~100  minichromosomal VSGs
VSGVSG VSG70bp70bp
177bp
~1000 chromosome-internal VSGs 
VSG
Pseudogenes or ESAGs 70bp
~15 expression-site (ES) associated VSGs
VSG
ESAGs P 70 bp
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1.7 Mosaic VSGs 
The presence of so many pseudogenes might at first suggest a very limited 
repertoire of VSG genes from which the parasite can draw during an infection. Although 
there are ~2000 VSG sequences in the genome, only ~400 are obviously capable of being 
used. What purpose could a repertoire of partial VSG genes serve? It appears that this 
repertoire of partial VSGs and VSG pseudogenes may actually be extremely important to 
T. brucei infection. Various studies have identified expressed VSGs that appear to have 
undergone incomplete gene conversion events, in which part of a VSG recombines with 
another VSG, resulting in new, chimeric, variants58-63. This chimeric VSG sequence is 
referred to as a “mosaic VSG” (Figure 1.7). Such mosaic variants are usually detected in 
vivo after the first few waves of parasitemia (~3 weeks of infection in a mouse)64.  
Reports of mosaic VSGs appearing only after the initial peaks of infection suggest 
that not only is the genomic repertoire of VSGs extended by the formation of mosaics, but 
that this extension of the repertoire may be required to sustain a chronic infection. That 
is, the repertoire of functional VSG genes is insufficient for escape from the host immune 
system over the course the months- or years-long infections observed in the wild65. 
Notably, the use of recombination for generating antigenic diversity within the genome is 
common to a number of pathogens that undergo antigenic variation, including Borellia 
burgdorferi66, Anaplasma marginale67, and P. falciparum68, so this may be a common 
strategy for immune evasion. Some studies have suggested an even greater extension of 
the VSG repertoire through the introduction of point mutations during gene conversion 
events69,70, although others argue that this is not a significant source of VSG diversity71. 
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Figure 1.7. Mosaic VSG can form by recombination between pseudogenes. 
 
 
1.7 Mechanisms of mosaic formation 
Although many instances of mosaic VSGs have been described, very little is 
known about when or where these variants form. It has been hypothesized that gene 
conversion in general and VSG switching in particular are facilitated by microhomology-
mediated end-joining in T. brucei72,73. Thus, this mechanism is expected to be involved in 
the formation of mosaic VSGs as well. A recent study attempted to tackle the formation 
of mosaic VSGs in vivo in depth by cloning and sequencing hundreds of expressed VSGs 
over the course of mouse infections64. In this extensive analysis, mosaic VSG donor 
sequences did indeed typically show homology with one another. It did not appear, 
however, that homology at the site of gene conversion was required for the formation of 
mosaic VSG genes; there were mosaic VSGs in which the boundaries of segmental gene 
conversion between donors showed absolutely no homology64. However, it is important 
to note that determining the precise source of donor sequence for each mosaic can be 
complicated, as the genomic VSG archive is complex and only partly known in this 
study64. Frequently VSG sequences share significant stretches of homology26,57 that can 
complicate analysis. 
Whether DSBs initiate the formation of mosaic VSGs, as is the case for GC 
switching in general, is not clear. Moreover, because most studies are limited to analysis 
of expressed VSGs and not the evolution of the genomic archive, is not clear where in the 
VSG pseudogenes
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genome mosaic VSGs form. The gene conversion events resulting in mosaic VSGs could 
occur within a telomeric BES or throughout the silent VSG archive. Because previous 
studies have been somewhat limited in resolution61,62,74-76, it has also been impossible to 
determine how frequently mosaic variants form. Although long recognized as an 
important aspect of antigenic variation in T. brucei, the mechanisms of mosaic VSG 
formation remain largely mysterious. 
 
1.8 Order in VSG switching 
Just as mosaic VSGs generally appear late in infection, it has been observed in 
many in vivo studies that other VSGs are more likely to arise early in infection47,77-80. 
While some work suggests that this can be explained in part by differences in growth rate 
(i.e. a variant that grows the fastest will appear first)78,81, this view has been challenged82. 
Telomeric VSGs are thought to arise early in infection47, followed by intact but non-
telomeric variants27,55. Finally, mosaic VSGs comprised of pseudogenes tend to appear 
after the other sets of functional VSGs have been expressed64. 
The factors driving this preference are not well understood, but a number of 
groups have attempted to explain the predicted order of VSG switching with modeling. 
One model suggests that the order observed during infection arises solely from parasite-
intrinsic factors, rather than the host milieu81.  Intuitively, it makes sense for genomic 
location to determine the probability of a switch to a given VSG: a VSG within a BES 
only requires that BES be activated, and a complete VSG near a telomere provides 
straightforward homology for transposition the active BES. Mosaic variants, on the other 
hand, are likely to be subject to frequent failure due to the requirement that a recombinant 
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VSG produce an in-frame open reading frame and a properly folding protein. Thus, only 
when the repertoire of complete and easily expressed VSGs has been exhausted do these 
harder-to-produce variants emerge.  
Other models, however, suggest that the activation probabilities of VSGs in 
different locations are not the only players in determining VSG order. Some suggest that 
genomic location in combination with the effects of immune cross-reactivity to certain 
VSGs83,84 determines VSG order during infection, while other models propose that the 
host immune system is the chief player in determining VSG order, primarily through 
cross-reactive epitopes85,86. A discussion of the specific ways in which the host immune 
response could affect VSG order and switching dynamics will follow in sections 1.12 
through 1.15. 
 
1.9 Dynamics of antigenic variation 
The extensive modeling of VSG switching in vivo highlights the fact that the 
dynamics of this process are a lingering question in T. brucei biology. Despite so many 
attempts at modeling5,78,81,82,84,85, little is known about the kinetics of VSG expression 
during infection. To date, the resolution of most studies of VSG switching in T. brucei in 
vivo has been quite low, examining only a handful of variants at any given time, such that 
these kinetics could not be measured directly47,79,80,87,88. Moreover, many factors on both 
the parasite and host side of this system work together to produce the observed peaks and 
valleys of parasitemia during infection, the VSGs arising within those peaks, and the 
VSGs cleared from those peaks. Parasite-intrinsic factors include the genomic archive of 
VSGs and the molecular mechanisms driving switching discussed previously, as well as 
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the rate at which switching occurs in a population. On the host side, the recognition of 
parasites by the host immune system and the dynamics and mechanisms of clearance of 
each variant will also likely affect the kinetics of observed VSG expression in vivo. 
 
1.10 Antigenic variation in vivo: Rates of switching 
A major parasite-intrinsic factor likely to affect VSG expression dynamics during 
infection is the rate at which switching occurs in T. brucei. Despite T. brucei’s large 
repertoire of VSGs, it is thought that the rate of switching must be tightly controlled. If 
switching is too slow, the immune system will recognize the expressed VSG and clear the 
infection, preventing transmission to the tsetse. If switching is too fast, it is possible that 
the VSG repertoire will be exhausted prematurely. Many measurements of VSG switching 
rates have been made, both in vivo and in vitro. In laboratory adapted strains the rates of 
switching have been measured to be between 10-5 to 10-7 switches/parasite/population 
doubling both in vivo87,89,90 and in vitro89-91. Many interpret the in vitro data to suggest 
that the process of switching is purely stochastic, but some studies have shown the rate of 
switching in naturally occurring (fly-transmitted) infections to be much higher, perhaps 
as high as 1 in 10087,88. These findings suggest that there may be some environmental cue 
initiating or influencing VSG switching.  
Determining the true rate of VSG switching during infection presents 
experimental challenges, however. Trypanosomes expressing different VSGs may grow at 
different rates, or trypanosomes may switch to a VSG for which the immune system has 
already mounted a full or partial response. As a result, even if a switch occurs, that 
switched variant may never establish in the measured population. Additionally, the non-
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dividing short stumpy form of T. brucei appears to be incapable of switching4. The 
number of short stumpy parasites present at any time fluctuates throughout infection5, 
and thus the number of parasites capable of switching at any given time also fluctuates 
throughout infection. 
 
1.11 Antigenic variation in vivo: Diversity 
One measure that may indirectly indicate the rate at which switching occurs in 
vivo, however, is VSG diversity within parasite populations. If switching occurs 
infrequently, populations should be relatively less diverse. Typically, antigenic variation 
is depicted by a schematic showing only one or a few variants per parasitemic peak 
(Figure 1.8). This model suggests a rate of switching just sufficient for immune evasion 
that also most efficiently preserves the VSG repertoire. Experimental data, however, 
suggest this is unlikely to be the case. The most comprehensive study of expressed VSG 
populations to date estimated, but did not measure directly, as many as ~100 VSGs could 
be expressed at any given time during an infection64. Other studies have also detected 
multiple VSGs expressed at the same time, though the experiments looked at so few VSGs 
that these observations are hard to interpret47,64,79,80,88. A recent study of parasites isolated 
from human infections also showed VSG diversity higher than the typical depiction of 
antigenic variation would imply92. This suggests that VSG diversity is not an artifact of 
the mouse infection model. It is also important to note that T. brucei is extracellular but 
not exclusively vascular. Trypanosomes can sequester in extravascular spaces93, and most 
studies so far have examined only populations in the bloodstream. This could lead to an 
underestimation of diversity and switching frequency in vivo. 
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Figure 1.8. VSG diversity in vivo.  
The textbook depiction of VSG diversity in vivo (left) shows only a handful of variants at 
each peak, but low-throughput experiments predict much higher diversity (right). The 
predicted model had not been tested at the time I started my studies. 
 
1.12 The B cell response to T. brucei 
 The dynamics of antigenic variation during an infection are likely to be affected 
by T. brucei’s interaction with its host, which determines the rate and mechanisms by 
which parasites are cleared, likely in response to each novel VSG. Given the parasite’s 
extracellular lifestyle, it is no surprise that the immune response to T. brucei is largely B 
cell mediated. A number of studies, however, highlight the complexity of the B cell 
response in the arms race between T. brucei and its host. One study reported non-specific 
polyclonal B cell activation in response to T. brucei infection94, although VSG-specific 
antibodies can also be detected during infection95,96. In addition, certain B cell 
populations have been reported to be lost during T. brucei infection, specifically IgM 
marginal zone B cells in the spleen. This loss of marginal zone B cells coincides with a 
loss of vaccine-induced protection against Bordetella pertussis in vaccinated mice 
challenged during T. brucei infection97. Overall, these studies and others98,99 suggest that 
B cell exhaustion may take place during T. brucei infection. This could occur either 
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directly through an interaction between the trypanosome and host, or perhaps more likely, 
through the constant presentation of new antigens via antigenic variation over the long 
course of infection. This, of course, could have an effect on the outcomes of antigenic 
variation in vivo. If B cell memory is lost, for example, it is likely that antigenic variants 
that occurred earlier in infection will reappear. Additionally, the diversity of VSG 
populations might increase over time, in synchrony with a weakening B cell response. 
Thus, an understanding of the dynamics of antigenic variation could shed light on the 
immune response to VSG, and an understanding of the immune response to VSG could 
shed light on the dynamics of antigenic variation.  
 In terms of antibody isotype, it is generally thought that IgM B cells mediate the 
response to T. brucei and VSG. This conclusion is based on a study tracking VSG-
specific antibody titers during T. brucei infections96 that showed IgM appearing earliest 
in infection and persisting longer than other isotypes. VSG-specific IgG did not appear 
until after the first peak of parasitemia was cleared, leading the authors to conclude that 
the IgM response was responsible for clearance of each variant. On the other hand, IgM-/- 
mice are still capable of maintaining a chronic infection100. Further complicating matters, 
IgM-/- mice express compensatory IgD101, an isotype whose function in the immune 
response is an enduring mystery102, as well as VSG-specific IgG2a and IgG3. Yet another 
study suggests that the anti-VSG antibody response is different from the response to other 
surface proteins103 in terms of isotype. This study did not determine whether this 
variability in antibody response could vary among different VSGs. Thus, the importance 
of IgM, in comparison to other isotypes, in the VSG-specific immune response remains 
an open question. 
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1.13 Antibody-parasite interactions 
The specific role of IgM in parasite recognition and clearance, though not yet 
clear, is critical for understanding how antibody interacts with VSG. Generally, it is 
thought that only the most N-terminal regions of the VSG can be recognized by antibody, 
due to the density of the VSG coat. The coat, extending ~12-15nM from the cell 
membrane104,105 is thought to “shield” invariant surface proteins as well as the relatively 
buried C-terminal domain of VSG from binding by host antibody106. This shielding of 
epitopes is important for immune evasion, as it prevents recognition of invariant epitopes, 
both on invariant surface proteins and in the relatively conserved VSG C-terminal 
domain. 
The specific role of each antibody isotype in recognizing VSG is important 
because it may determine the degree to which these epitopes are shielded. There is 
evidence that IgG can reach at least partially into the VSG monolayer107, though the 
integrity of the VSG coat is suspect in some experimental situations. Additionally, 
epitopes have been described that appear more membrane-proximal than expected, quite 
close to the buried end of the VSG, rather than at the exposed and variable N-terminus105. 
On the other hand, modeling of the protein structure of a handful of mosaic VSGs 
showed that many of the distinct residues on related mosaics occurred in the N-terminal 
portion of the VSG, likely to be exposed on the trypanosome surface and thus most 
immunogenic64. If the primary isotype recognizing VSG in a natural infection is IgM, 
VSG-internal epitopes may not be relevant to parasite clearance. Therefore, the epitopes 
recognized by the host are likely to be determined by the antibody isotype dominating the 
B cell response to VSG as well as by each specific antibody-VSG interaction. 
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Besides potentially shielding internal and invariant epitopes, the VSG coat 
functions to selectively degrade VSG-specific antibodies, thus dampening the host 
antibody response108. All endocytosis and exocytosis occurs through the flagellar pocket 
of the parasite109, and VSG is continuously endocytosed at this location110. The parasite 
quickly degrades antibody bound to endocytosed VSG while shuttling the VSG, now 
cleared of bound antibody, back to the surface. Though the precise molecular mechanism 
that underlies this process is not completely clear, it appears to occur through 
hydrodynamic-flow-mediated forces, with the bound antibody acting as a “molecular 
sail”.  Again, the specific isotypes recognizing VSG affect immune evasion: due to 
hydrodynamic flow, antibody-bound VSG reaches the flagellar pocket more quickly than 
bare VSG, and the bulky pentameric IgM molecule is cleared more quickly than other 
isotypes (e.g. dimeric IgG). Thus the rate of antibody degradation by T. brucei, which can 
result in evasion of complement-mediate lysis and opsonization, depends on the specific 
host antibodies targeting each VSG.  
 
1.14 Mosaic VSGs and antibody cross-reactivity 
The possibility of immune cross-reactivity between VSGs could also have 
consequences on the dynamics of antigenic variation in vivo. Mosaic VSGs are 
particularly interesting in this respect because they, by definition, share sequence 
homology with other VSGs in the genome. This is not exclusive to mosaic VSGs, 
however, as many genomic VSGs exist as members of closely related families26 that share 
stretches of sequence homology. Thus, the question arises: if similar VSGs are expressed 
during the same infection, can pre-existing immunity against a prior variant affect the 
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survival of a second variant? Studies of mosaic VSG epitopes suggest this is likely to be 
the case. A number of old studies in T. brucei and T. equiperdum, a related species of 
trypanosome that infects horses, actually identified mosaic VSGs by their immune cross-
reactivity61,62,74-76. In these experiments, monoclonal antibodies against a parent VSG 
were found to bind epitopes on other VSGs, which were later identified as mosaics. Some 
studies have shown, however, that point mutations alone can be sufficient to alter 
monoclonal antibody binding69,111. The recent study by Hall et al. identified mosaics with 
similar sequence that were nonetheless antigenically distinct, as antibodies raised against 
one variant would not cross-react with a related variant from the same infection. Thus, it 
is likely that VSG mosaicism can result in a mixture of unique and cross-reactive 
epitopes. The relative prevalence of each type of epitope and their relative influence of 
VSG dynamics and switching outcomes, however, is unknown. 
 
1.15 The T cell response to T. brucei and T cell recognition of VSG 
The T cell response to T. brucei has also been characterized112 and it appears to be 
central to eliciting an IFN-γ response during infection, which is a major determinant in 
resistance and susceptibility to infection113. Interestingly, although T cells have access to 
any VSG peptide, including the much more conserved VSG C-terminal domain, on study 
showed that T cells only present peptides from the more variable N-terminal domain 114. 
Somehow, the parasite manages to avoid immune recognition at invariant regions of the 
VSG. Thus, both arms of the adaptive immune system primarily recognize the variable, 
and exposed, N-terminal domain of VSG. 
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1.16 Outstanding questions 
The interaction between host and VSG, though it has been well studied 
throughout the years, is not yet well understood. It is still unclear precisely how VSG is 
recognized by antibody or how that results in parasite clearance. It is still unclear how 
often switching occurs in vivo. The determinants of order in VSG switching are still 
unknown. The mechanisms of mosaic VSG formation remain a mystery.  
 Overall, antigenic variation in T. brucei in the mammalian host occurs in the 
context of an extremely complex system. The first step towards understanding this 
complex system is to characterize it. The dynamics of this process are affected by the 
innate and the adaptive host immune system, density-dependent differentiation of the 
parasite, the probability of switching to different members of the genomic archive, and 
the relative fitness of individual parasites, at the very least. Nearly all of the studies on 
VSG switching rate and VSG switching outcomes have measured less than ten VSGs, for 
which either the sequence of the VSG gene was known or antibodies against the VSG 
existed47,79,80,87,88. Even more recent work cloning hundreds of VSGs over the course of 
infection64 could only detect the handful of variants present at any given time, though 
they suggest this was an underestimate.  
In this thesis I describe the development and application of a high-resolution 
method for measuring VSG expression in vivo. I have used this approach to describe the 
dynamics of antigenic variation during infection, which should provide a foundation upon 
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Given the limitations of existing methods for quantifying and identifying VSGs 
expressed in a population of parasites, I sought to develop a new method that could both 
identify and measure expression of VSGs in parasite populations. Ideally, the method 
would identify any VSG, as compared to methods relying on anti-VSG antibody which 
limit analysis to one or a few antigenic types49,88,89 and would be quite sensitive, so that it 
could be applied to the small parasite samples available from natural infections, for which 
parasitemia is often extremely low115. Furthermore, such a method would ideally be able 
to identify any VSG, including mosaic VSGs, the novel recombinants that arise during 
infection through segmental gene conversion and are likely to be important for long-term 
infection64. Along with its utility in identifying novel mosaic VSGs, a method capable of 
identifying any VSG would be useful for the analysis of wild parasite populations, for 
which no genomic VSG reference exists. 
Given these goals, high-throughput sequencing seemed an ideal approach for 
examining VSG expression in parasite populations. Producing hundreds of millions of 
reads, high-throughput sequencing is extremely sensitive, quantitative and, in 
combination with existing tools for transcriptome assembly116, capable of identifying 
expressed VSGs de novo. In this chapter, I describe the optimization of a high-throughput 
approach for sequencing VSGs, termed “VSG-seq”, which is quantitative and sensitive, 
works on small parasite samples, and does not require a reference genome.  
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2.2 Optimization of VSG-seq library preparation strategy 
There are many possible NGS approaches one can imagine that could solve the 
problems delineated above, and to identify the best approach for preparing VSG-seq 
sequencing libraries, I compared four possible protocols (Figure 2.1). Each protocol was 
designed to identify which aspects of the preparation were important for maintaining 
accuracy in quantification while also maximizing sensitivity and efficiency. I prepared 
starting material for all library preparations by mixing four T. brucei cell lines, each 
expressing a different VSG, in equal proportions. These control samples would allow me 
to assess the accuracy of quantification using each method. 
 
 
Figure 2.1. Schematic of four library preparation protocols. 
 
The first approach, “oligo-dT”, was used as a baseline for comparison. This 
protocol was a typical RNA-seq library preparation in which poly(A) mRNA is isolated 
and then fragmented, followed by generation of double-stranded cDNA (dscDNA) using 
random hexamers. The dscDNA was then used as the input material for an Illumina DNA 
sequencing library preparation kit.  
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The second approach, “VSG”, tested the degree of enrichment for VSG sequence 
accomplished by using a VSG-specific primer for 1st-strand synthesis. As an alternative to 
random hexamers, a primer against the conserved 14-mer in all VSG 3’UTRs was used to 
prime cDNA synthesis. 2nd-strand synthesis was performed as in the oligo-dT 
preparation, followed by enzymatic fragmentation of dscDNA. The fragmented material 
was used as input material for the same kit as in the oligo-dT protocol. Ideally this 
method would remain quantitative but, because the majority of sequenced material would 
be VSG mRNA, increase sensitivity.  
The third approach,  “VSG + SL 2nd Strand”, tested whether an alternative 2nd 
strand synthesis protocol, in which 2 rounds of VSG-specific PCR were performed to 
create dscDNA, could increase sensitivity even further. This method might also increase 
the proportion of reads coming specifically from full-length VSG mRNAs. 
The final protocol, “Amplicon”, tested whether simply sequencing VSG cDNA 
amplicons could increase sensitivity and enrichment for VSG sequence without 
compromising quantification. This protocol used the same VSG-specific primers as in the 
previous method, but increased the number of cycles of VSG PCR to 35.  
100bp single-end sequencing was performed on all prepared libraries, and VSG 
expression was measured by aligning reads to a reference genome made up of only the 
sequences of the VSGs mixed in the control populations. The number of reads aligning to 
each VSG was then counted. To calculate the percent of the population represented by 
each VSG, which should be 25% in all cases, the proportion of reads aligning to each 
VSG was divided by the total number of reads aligning to any VSG. It is important to note 
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that, because reads were aligned to a reference of only four genes, this analysis did not 
assess any possible noise or mapping issues that could result from VSG-seq analysis.   
This analysis revealed that all approaches were fairly quantitative (Figure 2.2A), 
showing values within 2-3 fold of the actual representation of each VSG. This variability 
could be due to variations in expression levels between individual VSGs or BESs, 
although the variation observed for each VSG was not consistent between protocols. This 
experiment was performed without replicates, however, so it is hard to interpret such 
variation. Overall, no method appeared significantly more biased than the others in terms 
of quantification.   
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Figure 2.2. VSG expression levels and enrichment measured by each protocol.  
(A) Graph showing VSG expression measured by each method. (B) Graph showing the 
total number of reads and number of reads aligning to VSG in each preparation. (C) 
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2.2.1 Enrichment for VSG sequences 
Because I observed little bias in quantification of VSG expression between 
methods, I chose to investigate whether enrichment for VSG sequence varied between 
library preparations. This was important for two reasons: (1) increased sequencing depth 
could improve sensitivity; and (2) enrichment for VSG would imply fewer “wasted” non-
VSG reads, providing more information per sequencing run and potentially allowing a 
higher degree of multiplexing per sequencing lane.  
Both “VSG” and “oligo-dT” showed a very small proportion of reads mapping to 
VSG (Figure 2.2B&C). Approximately 1% of mRNA sequence is VSG mRNA, which is 
expected given the high level VSG expression required in bloodstream form cells. Using 
only a VSG-specific primer for reverse transcription did not result in significant 
enrichment for VSG sequence. However, using a combination of this primer and a primer 
against the spliced-leader sequence resulted in the majority of reads mapping to VSG 
(Figure 2.2B). When compared to the proportion of reads mapping to VSG after the 
“oligo-dT” protocol (Figure 2.2C), “VSG + SL 2nd strand” increased enrichment to over 
40-fold, while amplicon sequencing increased enrichment to nearly 70-fold.  
 
2.2.2 Read coverage across VSG genes 
 Another concern in developing VSG-seq, besides enrichment for VSG sequence, 
is VSG sequence coverage. While enrichment can be high, this does not guarantee that 
coverage is uniform. Because one of the goals of VSG-seq was de novo assembly of 
VSGs, good coverage of each VSG is critical; otherwise, it would be impossible to 
reconstruct full-length VSG sequences. The reconstruction of full-length transcripts is 
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particularly important in the case of VSGs, because the 3ʹ end of the VSG, from which 
VSG is reverse transcribed, is the more conserved end of the VSG, and a reference 
database composed of 3ʹ VSG fragments would severely underestimate the extent of VSG 
diversity in any sample.  While reverse transcriptase may be processive enough to 
transcribe full-length VSG, the efficiency of this reverse transcription in the case of VSGs 
is unknown. To examine this, read coverage was visualized in Integrative Genomics 
Viewer (IGV)117,118, which visually depicts the mapping of each read to the reference 
genome (Figure 2.3). Only the PCR-based approaches showed unbiased coverage, further 
supporting the use of these methods for VSG-seq. Because amplicon sequencing would 
allow for the sequencing of the smallest samples, it was chosen for further analysis and 
optimization. 
In summary, I tested four different protocols, and chose an amplicon sequencing 
approach based on the following attributes: (1) Enrichment. Amplicon sequencing 
provided the most VSG sequence per library; (2) Coverage. Amplicon sequencing 
provided uniform read coverage across the entire VSG transcript; (3) Quantification. 
Amplicon sequencing was similarly accurate in quantification to the other methods 
tested; and (4) Input requirements. Amplicon sequencing required the smallest amount of 
starting material, because VSG cDNA is amplified by PCR during the library preparation  
	  






Figure 2.3. Read coverage across VSG transcripts. 
Screenshots from IGV visualization of alignments of reads to VSG-2 from each library 
preparation. Each row shows an alignment of a subset of reads (bottom) and overall read 
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2.3 Optimizing VSG-seq analysis: mappability  
 After identifying VSG amplicon sequencing as the best approach for VSG-seq, I 
optimized the analysis parameters for this approach.  In the previous analysis, sequences 
were only mapped to a reference genome containing VSGs known to be in the sample. 
This simplified quantification, but ignored a major issue with sequencing VSGs: 
mapping. Portions of VSG sequences are frequently very similar or identical26, such that 
it is likely that a given 100-bp read cannot map uniquely to certain regions within the 
VSG it arose from. Uniquely mapping reads are required for accurate quantification of 
expression, however, and quantification of multiply mapping reads (without the aid of 
some complicated analysis algorithms that have not yet been developed) will always 
result in the over- and/or underestimation of VSG expression.  
An analysis of the annotated Lister 427 VSGnome reference confirmed that 
mapping is a concern when analyzing VSG sequences. To assess the “mappability” (the 
proportion of reads which can uniquely map) of the VSGnome, 100bp reads were created 
from each reference database, representing all of the possible reads that could result from 
each VSG sequence. These simulated reads were then mapped back to the reference, 
allowing for only uniquely mapped reads with no more than 2 mismatches per read. A 
number of databases were analyzed, using different sets of VSGs, and the mappability of 
each VSG was calculated by dividing the number of reads mapping to that VSG by the 
number of reads that would map to the VSG if its sequence were completely unique. For 
example, if only 50% of the sequence of a VSG is unique to that VSG, that variant will be 
50% “mappable”. This analysis shows that as the number of VSGs in a reference database 
increases, the mappability of the VSGs within that database decreases (Figure 2.4).  A 
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simple count of reads mapping to each VSG, then, will result in an underestimate of 
expression for VSGs that are less unique and an inability to quantify the expression of 
VSGs that have no unique sequence at all.  
To assess the degree to which mappability affects quantification in a real 
sequencing experiment, I aligned the sequences generated from the amplicon sequencing 
library described earlier in this chapter to the Lister 427 reference VSGnome and 
quantified abundance either using cufflinks119, an algorithm with little correction for 
mappability, or MULTo120, a program specifically designed to correct for the mappability 
of each gene. This analysis shows that correction for mappability does indeed affect 
expression measurements generally (Figure 2.5A) and in the case of the specific VSGs in 
the control library (Figure 2.5B). Cufflinks, which does not correct for the uniqueness of 
each sequence, hugely overestimates the abundance of VSG-2, while it underestimates 
VSG-832. These errors are proportional to the mappability of each VSG. Thus, VSG-seq 
can only accurately measure VSG expression when a tool to correct for mappability, such 
as MULTo, is used. All further analyses, unless otherwise noted, used MULTo for 
quantification of VSG expression.  
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Figure 2.4. Mappability of different VSG databases.  




2.4 Characterizing VSG-seq 
After identifying the ideal parameters for preparing and analyzing VSG-seq 
libraries, I wanted to assess the final protocol. Specifically, I sought to determine the 
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the limit of detection or quantification of VSG expression. To do this, I again prepared 
control mixtures of parasites. An outline of this experiment is provided in Figure 2.6. 
Briefly, I prepared two sets of mixtures in triplicate, from seven lines, each expressing a 
different VSG.  In one set (Library A), cells were mixed in ten-fold dilutions, and in the 
other (Library B) cells were mixed in equal proportions. After preparing these mixtures, 
either 1 million or 10 million cells were used to make VSG-seq libraries. For these 
experiments, and all further VSG-seq experiments, a newer, low-input DNA sequencing 





Figure 2.5. Comparison of quantification using MULTo or cufflinks.  
(A) Scatter plot showing measured FPKM for all VSGs using each algorithm. (B) Bar 
chart showing relative expression of each VSG in control mixture. The black bar 
(“Expected”) represents the proportion of cells expressing that VSG in each control 
mixture, and the gray bars represent quantification for each library using MULTo or 
cufflinks. 
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Figure 2.6. Schematic of creation of control libraries for validation.  
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2.4.1 Assembly of VSGs and relationship to number of input cells 
Although previous analyses show that VSG expression could be quantified using 
the Lister 427 reference, this reference is useless for analysis of any strain without a 
reference VSGnome or for the analysis of expression of mosaic VSGs, because mosaic 
variants generated by segmental gene conversion during the course of an infection are, by 
definition, absent from any reference genome. Thus, it was critical to test whether a 
useful VSG reference could be assembled de novo. I used Trinity, a transcriptome 
reconstruction method designed specifically for the reconstruction of alternative 
isoforms, for de novo assembly of VSGs116. I reasoned that this tool might be suitable for 
the reconstruction of VSG transcripts, which often share many stretches of homology, 
especially in the case of mosaic VSGs. I tested Trinity’s assembly using Library A in 
order to determine whether assembly required some level of coverage for accurate 
reconstruction of a VSG transcript. This analysis revealed that Trinity could successfully 
assemble full-length or nearly full-length VSG sequences from as few as nine cells in the 
control mixture (Figure 2.7). It is important to note that Trinity also assembled VSG 
transcripts that were not expressed in the control mixtures, which probably represent 
transcriptional noise in each cell.  
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Figure 2.7. Efficiency of assembly using Trinity.  
Graph showing the fraction of each VSG assembled (mean +/- SD) compared to the 
number of cells in the population. 
 
2.4.2 Limits of quantification of VSG expression 
After aligning reads to the Trinity-assembled reference genome (in the case of 
Library A; Library B was quantified using the Lister 427 reference VSGnome), I 
determined that VSG-seq is capable of quantifying a variant’s presence within the 
population, for variants present above 0.1% of the population (Figure 2.8A), within a ~2-
5-fold range (Figure 2.8B). VSG-seq could quantitatively detect variants present on 
0.01% of parasites; all assembled VSG sequences that were not present in the control 
mixtures were measured at less than 0.01% of the population (Figure 2.8C), while 
variants present at <0.1% of the control mixture all showed values between 0.01-0.1%. 
The apparent overestimation of less abundant VSGs in this control experiment is likely a 
result of low-level switching in the more abundant components of the mixture, or low-
level transcription of silent VSGs. The limits of detection and quantification for VSG-seq 
appear to be independent of starting cell number, as control mixtures made from 106 or 
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Figure 2.8. Quantification of VSG expression in control libraries. 
(A) Quantification of VSG expression in control library (mean +/- SD), in which cells 
were mixed in ten-fold dilutions. The black bar (“Expected”) represents the proportion of 
cells expressing that VSG in each control mixture, and the gray bars represent 
quantification for each library using VSG-seq. (B) Quantification of VSG expression in 
control library (mean +/- SD) in which cells were mixed in equal proportions. Note that 
the analysis of this library was performed using the Lister427 VSGnome database, rather 
than an assembled reference genome. (C) VSG expression calculated for VSGs absent 
from the control mixture in Figure 1 (mean +/- SD). Although some VSGs are assembled 
and quantified below 0.01%, these do not appear to correspond with VSG protein in the 
population. The single point above 0.01% is likely the result of a parasite that has 
undergone switching in one replicate, as this VSG is expression-site associated and is 
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2.5 Discussion  
These experiments demonstrate that VSG-seq is both quantitative and sensitive. 
The optimized method, based on sequencing of VSG amplicons, maintains accuracy in 
quantification even after 35 cycles of PCR, so even very small samples can be analyzed. 
Most importantly, the approach relies on de novo assembly of VSG transcripts from 
sequencing reads to identify VSGs present in a parasite population. This approach, an 
alternative to methods relying on anti-VSG antibodies, can be applied to any sample, 
regardless of one’s knowledge of the parasite’s genomic VSG repertoire.  
Of course, there are aspects of this method that can complicate analysis and which 
are important to keep in mind when analyzing VSG-seq data.  First, the limit of detection 
of VSG-seq is neither a number of cells nor a number of reads, but rather a proportion of 
the sample of parasites analyzed. This is likely due to transcriptional noise in every cell. 
In these control samples, at least, it is likely that this noise arises from similar genomic 
sources (silent BESs or chromosome-internal VSGs which fall near a promoter are 
possibilities) and these transcripts are present at a level of about 1 per 10,000 VSG 
transcripts. Thus, when analyzing a sample of 106 parasites, any VSG present on less than 
100 parasites will not rise above the level of this noise. This is unfortunate, because these 
extremely rare variants could be extremely interesting biologically. An approach that 
could determine VSG expression in individual cells, such as single genome sequencing121, 
could be used to determine the precise level of transcriptional noise in individual 
parasites. Another complicating aspect of this detection limit is that smaller samples 
(<10,000) allow, in theory, for detection of all variants. These control experiments only 
tested samples isolated from 106 parasites; further characterization of libraries made from 
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smaller numbers would be beneficial to understanding the limitations of VSG-seq. In 
patient samples, for example, which may only contain hundreds of parasites, an 
understanding of the limits of detection for library preparations made from small samples 
may be critical to interpretation of VSG-seq data.  
Another aspect of this method that is important to consider is the issue of 
mappability. Quantification relies on corrections for mappability but in cases where sets 
of VSGs are very similar, there may be no unique region of certain VSGs and no 
straightforward way to correct for this. Although this has not been a major issue in my 
experiments, in some situations, perhaps later in infection when mosaic VSGs dominate, 
this could be an important consideration for accurate VSG-seq analysis.  
Along these same lines, read mapping can limit the diversity detectable within a 
population. Due to the error rate of high-throughput sequencing122, it is typically to allow 
read mapping with mismatches. To effectively map reads to assembled VSGs, this 
analysis requires that assembled VSGs sharing >98% sequence identity be “collapsed” 
into one representative VSG sequence. Thus, some degree of diversity at the nucleotide 
level can be lost during this analysis. An alternative approach would be to allow no 
mismatches during read mapping, but this could compromise the sensitivity of the 
approach. 
Overall, however, these experiments have shown that VSG-seq works well on 
samples isolated from in vitro cultures. In the next chapter, I will examine the feasibility 
of the technique when applied to samples collected from the blood of infected animals.  
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CHAPTER 3.  VSG expression during acute T. brucei infection 
 
3.1 Introduction 
After optimizing VSG-seq in vitro, I next piloted the approach in samples 
collected from mice infected with the well-characterized but highly virulent Lister 427 
strain of T. brucei. This strain was chosen because we have some knowledge of its 
switching behavior in vitro, to which in vivo results can be compared49,54. Although the 
Lister 427 strain has been well characterized in vitro, little is known about antigenic 
variation in the strain in vivo. The strain was ideal for a pilot experiment because the 
Lister 427 reference VSGnome could be used to validate assembled VSGs. This pilot 
experiment would demonstrate the applicability of VSG-seq to samples collected from 
animals, in addition to possibly providing new information about this strain’s switching 
behavior in vivo.  
 
3.2 Infection dynamics vary between mice 
For this pilot, five Balb/cByJ mice were infected intraperitoneally (i.p.) with ~5 
wild-type Lister 427 parasites expressing VSG-2. Five parasites were used to initiate 
infection in order to keep infections clonal, so that any variants detected at later times 
would represent true switch events and not the outgrowth of a rare variant present upon 
infection. Indeed, in experiments described in Chapter 6, I found that an increased 
parasite inoculum does appear to increase observed diversity. Parasitemia in tail blood 
was monitored daily by hemacytometer. Once parasitemia was detectable, parasites were 
collected by submandibular bleed. The vast majority of red blood cells (RBCs) were 
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removed from each sample using magnetic-activated cell sorting (MACS) with anti-
Ter119 beads, which I determined to be a better method for smaller numbers of parasites 
than the DEAE cellulose protocol used extensively in the past123. 
 
 
Figure 3.1. Parasitemia during acute infection.  
Graph showing parasitemia in each of five mice during infection, as measured by 
hemacytometer. “low” indicates parasites could be detected, but parasitemia was too low 
to quantify accurately. Arrows indicate when samples were collected for VSG-seq; 
samples were only collected in those mice in which parasitemia was measureable. 
 
The dynamics of infection in each of the five mice varied significantly (Figure 
3.1). One mouse never established an infection, which was most likely due to the dilution 
of injected parasites, suggesting that these were in fact clonal infections. If, as intended, 
the injection of  ~5 parasites effectively results in 1-2 parasites initiating each infection, 
infrequently a mouse will receive an inoculum containing no parasites and will not 
become infected, as seen in this experiment. Two mice (Mice 1 and 5) succumbed to 
infection at day 6 p.i., without clearing the first wave of parasitemia, a common 
occurrence in infections with this particular T. brucei strain, which reaches high levels of 
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parasitemia due to its inability to respond to quorum sensing factors124. Two mice, 
however, managed to control infection beyond the first week. Interestingly, one of these 
mice (Mouse 2) did not show detectable parasitemia (>105/ml) until day 11. The last 
mouse (Mouse 4) showed more typical dynamics, clearing a first peak of parasitemia 
around day 6, followed by a second parasitemic peak before succumbing to infection. 
These variable dynamics presented an interesting scenario in which to investigate 
antigenic variation: do they relate to the repertoire of VSGs expressed in each infection, 
or are they related to the individual immune systems of each otherwise congenic mouse? 
Although these mice are clonal, their immune systems, and their B cell repertoires in 
particular, are highly and divergently polyclonal125.  
 
3.3 Analysis of variants in mice unable to control the first peak of parasitemia 
Analysis of the two mice that could not control the first wave of parasitemia 
revealed switching behavior similar to what is observed in vitro in this strain. At the end 
of both infections, >99% of parasites express the starting variant, VSG-2, and a small 
number of parasites, almost all at <0.1%, express 4-5 other VSG types. 7 unique variants 
were identified between the two infections, of which two are present in both infections. 
Five of these variants are known to be present in a BES32. While the genomic position of 
VSG-12 is uncertain, this variant is commonly seen in populations of switchers in Lister 
42754,126. Interestingly, a new VSG was assembled from and expressed in both 
populations. It is likely that this variant is absent from the Lister 427 reference database 
because this database is based on the Lister 427 “single marker” line127, and the cells used 
in this experiment were the wild-type line from which the single marker line was derived.  
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Figure 3.2. Early VSG expression.  
Quantification of VSG expression in Mouse 1 (A) and Mouse 5 (B). Note that the y-axis 
is on a log scale and colors do not correspond between graphs. 
 
Overall, the population of switchers in each mouse is quite similar and consistent 
with switched populations observed in vitro, suggesting that antigenic variation may not 
be influenced by host factors, at least in this strain at this early stage of infection.  
 
3.4 Analysis of first relapse peaks in mice that control infection temporarily 
 Analysis of the later time points collected from Mice 2 and 4 showed surprising 
VSG diversity, at least in contrast to the simplified though prevalent model of switching 
in which one or a few variants make up each parasitemic peak. In both infections, 9 
variants besides the starting variant, VSG-2, could be detected (Figure 3.2 and Figure 
3.3). In total 14 variants are detected between both infections, 5 of which appear in both. 
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section, again demonstrating that switching preferences in this strain in vivo resemble 
those observed in vitro, and that switching preference is consistent between infections 





Figure 3.3. VSG expression across initial and first relapse peaks. 
(A) Pie charts showing relative expression of each VSG at each time point analyzed in 
Mouse 4. (B) Graph showing parasitemia in this infection, with collection times indicated 
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Examining each infection individually reveals a number of other interesting 
aspects of VSG expression in vivo.  Mouse 4 shows a peak of parasitemia with 
approximately the same timing as the peaks in Mice 1 and 5 and, indeed, the makeup of 
this peak resembles that of Mice 1 and 5. Analysis of the later time points in this infection 
show that the rare variants from day 6 make up the more abundant variants on day 11, in 
roughly the same proportions. Interestingly, however, two VSGs appear on day 8 but are 
absent from the population on day 11, suggesting that there may be some competition 
between VSGs in vivo, causing certain variants to fail within a population.  
 
Figure 3.4. VSG expression in the absence of an initial parasitemic peak. 
(A) Pie charts showing relative expression of each VSG at each time point analyzed in 
Mouse 2. (B) Graph showing parasitemia in this infection, with collection times indicated 
by an arrow. (C) Line graph showing change in expression in each VSG over time.  
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Mouse 2 never shows a first parasitemic peak, but nevertheless shows clearance 
of VSG-2 by day 12, the first time populations were analyzed. This shows that VSGs can 
be expressed and cleared by the host immune system even when parasitemia is very low 
or undetectable, and that variants need not be abundant to be cleared.  
 
3.5 Discussion 
Overall, these experiments demonstrate that VSG-seq works well when applied to 
samples collected from an infected animal. All VSGs assembled matched annotated VSGs 
from the Lister 427 strain, and most early variants were BES VSGs, consistent both with 
observations in vitro and with the prevailing model of switching hierarchy in T. brucei, in 
which telomeric VSGs appear earliest in infection. Moreover, the experiments 
demonstrated the power of de novo assembly for identifying VSGs, as a new VSG was 
discovered in two infections.  
The variation in infection dynamics among the four infections raises interesting 
questions about VSG dynamics in vivo. Though all infections were initiated with 
genetically identical parasites, control of the infections was quite variable, suggesting that 
the host immune system could play a large role in the measureable outcomes of VSG 
switching. Specifically, the dynamics observed in Mouse 2 show that some variants may 
be cleared even when present in small numbers. This is likely due to the germline B cell 
repertoire unique to this mouse125. That is, this Mouse 2 may have had pre-existing 
antibodies recognizing VSG-2, resulting in early clearance of this variant and suppression 
of the first parasitemia peak. Thus, although switching may occur in a rough order, with 
some probability for certain variants to be chosen before others, the observable outcomes 
	  
	   48 
of switching may be largely shaped by the B cell repertoire of a given host. The dynamics 
of this particular infection also emphasize the importance of analyzing parasite 
populations even at very low parasitemia. During the time when parasitemia was 
undetectable, VSG-2 was cleared and another variant took over as the major VSG within 
the population. The dynamics of this process were missed because samples were not 
collected during this time. 
Despite the variation in infection dynamics between these four infections, all of 
the infections have one thing in common: substantial and unexpected VSG diversity, 
particularly as infection progressed. However, because these later time points also 
represented terminal time points, it remained unclear whether this was a common feature 
of antigenic variation in vivo or a consequence of terminal parasitemia at the time of 
sample collection. To determine whether this diversity is characteristic of long term T. 
brucei infection, which is a more relevant biological context, I next investigated VSG 
expression dynamics during infections with a less virulent trypanosome strain that 
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CHAPTER 4.  VSG expression in vivo during chronic T. brucei infection 
	  
4.1 Introduction 
After analysis of acute infections with a virulent strain of T. brucei, it became 
clear that a more chronic model of infection would be required to answer questions about 
long-term VSG expression dynamics in vivo. Such an infection model is more relevant to 
natural infections, which can last months or even years65, and certain aspects of antigenic 
variation that may be critical to natural infections, such as the appearance of mosaic 
VSGs or the effects of immune system exhaustion on VSG dynamics, are likely only to be 
measurable after weeks of infection. To analyze VSG dynamics during a chronic 
infection, I used the EATRO1125 strain of T. brucei128,129, which produces infections of 
at least 30 days, or approximately 4 parasitemic peaks, in a mouse.  
 
4.2 VSG diversity and dynamics during early infection 
To measure VSG expression within populations of T. brucei, I infected four mice 
with ~5 EATRO1125 parasites. This strain had originally expressed VSG AnTat1.1 128,129 
but was now heterogeneous, such that each infection was initiated with a distinct VSG. I 
tracked VSG expression dynamics for 30 days (Figure 4.1 and Figure 4.2; the raw data 
produced by these experiments and used for these analyses can be found in the published 
version of this work130). A few variants made up the majority of the population at each 
time point analyzed, but, surprisingly, each sample also contained many rare variants that 
would have been undetectable using previous methods for characterizing VSG 
populations. Variants typically persisted for approximately 7 days followed by quick 
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clearance from the population, although some variants deviated from this pattern. 
Notably, all infections showed great diversity even within parasitemic valleys. VSG-seq 
identified an average of 28 variants at each time point analyzed during the first 30 days of 
infection (Table 4.1).  
 
Figure 4.1. Dynamics of VSG expression during early infection in (A) Mouse 1 and 
(B) Mouse 2.  
Each colored line represents an individual VSG’s presence in the population, while the 
black line represents total parasitemia. Only variants present at greater than 0.1% of the 
population at that time point are shown. When parasitemia could not be measured by 
hemacytometer (<106/ml), parasitemia is artificially set at 105/ml to allow for 
visualization of the population. Note that, because there are so many VSGs expressed 
during infection, colors are difficult to distinguish; overall, variants do not reappear later 
in the same infection. A smooth curve connects points where expression or parasitemia 
was measured; these curves are for visualization and do not imply the actual kinetics of 
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Figure 4.2. Dynamics of VSG expression during early infection in (A) Mouse 3 and 
(B) Mouse 4.  
Each colored line represents an individual VSG’s presence in the population, while the 
black line represents total parasitemia. Only variants present at greater than 0.1% of the 
population at that time point are shown. When parasitemia could not be measured by 
hemacytometer (<106/ml), parasitemia is artificially set at 105/ml to allow for 
visualization of the population. Note that, because there are so many VSGs expressed 
during infection, colors are difficult to distinguish; overall, variants do not reappear later 
in the same infection. A smooth curve connects points where expression or parasitemia 
was measured; these curves are for visualization and do not imply the actual kinetics of 
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Table 4.1. Variants present during infection. 
Table of the number of VSGs present at each time point. Any variants quantified as 
greater than 0.01% of the population are included. 
 
 
Figure 4.3. Dynamics of VSG expression during late infection (d96-105) for Mouse 3.  
Each colored line represents an individual VSG’s presence in the population, while the 
black line represents total parasitemia. Only variants present at greater than 0.1% of the 
population at that time point are shown. When parasitemia could not be measured by 
hemacytometer (<106/ml), parasitemia is artificially set at 105/ml to allow for 
visualization of the population. Note that, because there are so many VSGs expressed 
during infection, colors are difficult to distinguish; overall, variants do not reappear later 
in the same infection. A smooth curve connects points where expression or parasitemia 
was measured; these curves are for visualization and do not imply the actual kinetics of 
variant expression between points. 
Number of VSGs expressed
d6 d7 d12 d14 d18 d21 d24 d26 d30 d96 d99 d102 d105
Mouse 1 15 18 21 34 36 6 83 33
Mouse 2 10 34 15 53 57 36 29 39
Mouse 3 9 13 9 22 21 14 30 21 58 66 30 32
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4.3 VSG diversity and dynamics during late infection 
One mouse (Mouse 3) survived much longer than the other three (106 days, 
compared to 41-72 days), allowing for close analysis of longer-term infection dynamics. 
Although in the later stages of this infection VSG dynamics did appear qualitatively 
different with variants persisting longer before clearance (Figure 4.3), possibly due to 
immune system exhaustion, parasite populations remained diverse, with 30-66 variants 
detectable at each sampling (Table 4.1). The increased survival and lower diversity in this 
mouse are also likely due to the polyclonal germline B cell repertoire of this mouse125, 
rather than the initiating VSG, as VSG identity has not been shown to affect trypanosome 
growth rate or induction of the immune response77,131.  
 
4.4 There is a preference for certain VSGs during infection 
To see if these infections showed any bias or hierarchy in VSG expression47,78-80, I 
compared the VSG repertoires of all four mice during the first 30 days of infection, in 
which 192 VSGs were expressed in total. Although each infection initiated with a 
different major VSG, the majority of variants (86%) appeared in more than one infection, 
and nearly half (46%) appeared in all four infections (Figure 4.4A). 97 VSGs were 
expressed in Mouse 3 from days 96-105. I compared later-occurring VSGs with those 
expressed early in Mice 1, 2, and 4, and found none in common, even though early 
variants from Mouse 3 also appeared frequently in Mice 1, 2, and 4 (Figure 4.4B). 
Overall, these experiments revealed striking diversity within each infection, but 
surprisingly frequent occurrence of the same VSGs in different infections. Unfortunately, 
these experiments cannot be used to address the question of order or hierarchy in 
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switching during infection because they each initiate with different VSGs and a 
comprehensive assembly of the genomic VSG archive for this strain was not finished at 
the time of analysis.  
 
Figure 4.4. Overlap in expressed VSGs across infections. 
(A) Intersection of sets of VSGs expressed during early infection (d6-d30). The total 
number of VSGs is listed in parentheses below the mouse number. (B) Venn diagrams 
showing intersection of VSGs expressed early in infection (VSGs from Mouse 1, 2, or 4 
vs. VSGs from Mouse 3, d7-30) and intersection of VSGs expressed early in infection 
with VSGs expressed late in infection (VSGs from Mouse 1, 2, or 4 vs. VSGs from Mouse 
3, d96-105). 
 
4.5 Many expressed VSGs never establish in vivo 
Within these diverse parasite populations, many variants appeared transiently at 
low levels. I have termed these ‘minor’ variants. By examining the fate of every VSG, I 
found that at any time during the first 30 days of infection about half (53%) of the 
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variants present never reach 1% of the population (Figure 4.5A). This mirrored the 
observation of failed variants during acute infection described in Chapter 3. The 
frequency with which variants failed suggested this could be an important phenomenon 
affecting the measureable outcomes of VSG switching, and led to the question of what 
determines VSG fitness.  
 
Figure 4.5. Emergence of minor variants during infection. 
(A)Minor variants present at each time point (mean +/- SD). A minor variant is arbitrarily 
defined as any VSG that never exceeds 1% of the population during the course of 
infection in a single mouse.  Major variants are any variant that exceeds 1% of the 
population at some point during infection. (B) Venn diagram comparing the fates of 
VSGs appearing in all four infections. 
 
To investigate the possibility that certain VSGs, when expressed, conferred some 
intrinsic fitness to parasites within the population, I compared the fates of VSGs that 
appeared in all four infections. Of the 48 VSGs that appeared in all infections, few were 
consistently dominant and few were only ever expressed as a minor variant (Figure 
4.5B). This implies that variant success is not determined by the expressed VSG alone. 
Instead, variant success is likely to be determined by interactions between the parasite 
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and the humoral immune response in each animal. However, there were a handful of 
VSGs that were consistently either major or minor. It is possible that these variants do 
confer some fitness advantage or disadvantage that overcomes the effects of immune 
cross-reactivity or the germline B cell repertoire.  
 
4.6 Detection of mosaic VSGs 
T. brucei’s genomic VSG repertoire consists of a high proportion of incomplete 
VSG genes or pseudogenes26,27. Indeed, the 289 VSGs observed in these infections may 
represent over half of the complete VSG repertoire (~400 complete and predicted to be 
functional VSGs for the Lister427 strain26, and ~500 for EATRO1125, according to a 
recent assembly of the VSGnome for this strain completed in collaboration with George 
Cross). The 65-135 VSGs observed before day 30 could represent up to one-third of the 
pre-existing repertoire. Thus, there is pressure on the parasite to diversify its genomic 
repertoire to sustain infection, namely by the formation of mosaic VSGs.  
Though previous studies had noted that mosaics tend to arise later in infection, or 
at least after about 3 weeks of infection in a mouse, they did not determine when these 
variants form within the genome, or how61,64,76. It is unknown whether mosaic VSGs form 
at the active expression site or within the silent repertoire prior to expression. To identify 
possible mosaics, I compared expressed VSG sequences to two independently assembled 
genomes for this parasite graciously made available by Keith Matthews and Isabel Roditi. 
Because of limitations in the amount of material available at each time point, I could 
choose only a few candidates for validation. Candidate VSGs were identified based on 
three criteria: (1)  <80% of the VSG length aligned to any sequence in either genome, 
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which suggested a novel variant absent from the parent genome; (2) the VSG was 
expressed in only one infection, which provided evidence the VSG resulted from a novel 
recombination event; and (3) the VSG was expressed at >0.1% of the population, 
meaning it would be more easily detected by PCR. To test that these were true mosaics 
and to determine when they formed within the genome, I used VSG-specific primers to 
confirm their absence from the genome of the parental strain and presence within gDNA 
collected during infection. I identified three mosaic VSGs using this approach. In each 
case, the mosaic VSG was only detectable by PCR when it was also being expressed 
within the parasite population (Figure 4.6). With the caveat that parasites were not 
sampled daily, this suggests that mosaic formation occurs, at least in these cases, shortly 
before expression with subsequent transposition into the active expression site, or directly 
within the active expression site.  
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Figure 4.6. Identification of mosaic VSGs.  
(A) Transient expression of a mosaic VSG in the population, and PCR confirmation of the 
mosaic is shown below. The black line represents total parasitemia at each day post 
infection, and the green line represents the number of parasites expressing the mosaic 
VSG. “n.q.” (not quantifiable) indicates that the VSG is detectable within the population, 
but not quantifiable. “n.d.” indicates that the VSG is not detectable within the population. 
Below the graph are products from PCR of gDNA at each time point, using either primers 
specific for the mosaic VSG or the control gene, ura3. This VSG could not be amplified 
when first detected by VSG-seq, likely because of low cell numbers in the DNA sample 
(probably less than 10 cells). (B) and (C) depict mosaics from late infection with PCR 
confirmation of the mosaic shown below. 
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4.7 Discussion 
My results indicate that VSG switching does not occur at a rate just sufficient for 
immune evasion, with only a few variants present at any time. Instead, as suggested in the 
previous experiments in acute T. brucei infections, high VSG diversity seems to be a 
universal aspect of infection that persists throughout infection. This was suggested 
previously but never measured directly64. In contrast to experiments in the Lister 427 
strain, however, diversity in EATRO1125 infections appears to be much higher. Whereas 
9 VSGs were observed at the first relapse peak in acute infections, an average of over 28 
variants were observed at any point during a chronic infection. It is hard to say whether 
this difference in diversity is meaningful, as only a handful of mice have been analyzed 
so far for either strain, but the difference could be due to differences in switching rates, as 
it has been suggested, though never concretely quantified, that pleomorphic parasite 
strains producing chronic infections switch at a higher rate than lab-adapted strains88.  
Beyond simple VSG diversity, antigenic similarity between VSGs may result in 
the quick elimination of certain variants by cross-reacting antibodies, rendering such 
variants useless, and making the effective VSG repertoire even smaller than the intact 
genomic repertoire would suggest. Thus, recombinatorial mechanisms that expand the 
pre-existing VSG repertoire may be critical for sustaining a chronic infection, and mosaic 
VSG formation is likely necessary to increase repertoire diversity as infection progresses. 
My results show that much of the intact VSG repertoire is likely to have been expended 
early in an infection, as a result of expression and subsequent recognition by the immune 
system. Therefore the pre-existing repertoire of complete VSGs within the genome is 
probably insufficient to support the sometimes years-long infections observed in the 
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wild65. Although parasitemia is much lower in natural hosts, pre-existing immunity is 
common in native mammals132, providing an alternative pressure to diversify the VSG 
repertoire.  
In addition to highlighting the importance of mosaic VSGs in a chronic infection, 
these experiments demonstrate that VSG-seq can be used to successfully identify these 
novel variants. More importantly, these experiments give the first mechanistic insight 
into mosaic formation. By tracking the presence of a mosaic VSG in the genome over 
time, I found that mosaic VSGs probably form primarily within the active expression site, 
rather than elsewhere in the genome followed by subsequent transposition as a complete 
and functional VSG into the BES, because the mosaic VSGs identified were never 
detectable at the genomic level before they could be detected at the RNA level. Due to 
the lack of a well-annotated reference VSGnome, it was impossible to determine the 
patterns of mosaic formation, but this will be an interesting question in the future. Where 
did recombination occur in these examples of mosaicism? Based on the location of the 
primers used for confirmation, it appears that all of the mosaic VSGs identified formed 
through recombination in the 3ʹ end of the VSG. This mechanism of mosaicism has been 
observed before59,60,63,133 and is referred to by some as 3ʹ donation64. The fact that all 
mosaics identified might have formed by this mechanism is interesting, as it suggests that 
the majority of recombination events could occur in the presumably shielded C-terminus 
of the VSG, which may or may not play a role in immune recognition. What, then is the 
purpose of such VSG diversification? It will be interesting to follow up on these 
experiments and determine whether the introduction of mutation into the C-terminal 
domain of the VSG is ever capable of conferring resistance to host antibody.  
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Finally, these experiments revealed a significant preference for parasites to switch 
to certain VSGs, another aspect of switching long speculated to be true47,78-80. The 
infections described in this chapter, however, were each initiated with a different VSG. 
This suggests that preference is at least somewhat independent of the initiating VSG, but 
also makes a detailed analysis of order in VSG switching, if any such order exists, very 
difficult. A specific investigation of order in VSG switching that takes advantage of an 
annotated VSGnome for this parasite strain will be needed to tease out the determinants 
of hierarchy in VSG switching.  
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CHAPTER 5.  Further applications of VSG-seq 
	  
5.1 Introduction 
 VSG-seq revealed interesting aspects of VSG dynamics in vivo in experimental 
mouse infections, but one of the most exciting aspects of the approach is its broad 
applicability. It can be used on any T. brucei population, including parasites grown in 
vitro, parasites from natural infection, or even parasites within other niches outside of the 
bloodstream. A fast, high-resolution approach to profiling any of these populations was 
previously unavailable. In this chapter, I will discuss further applications of VSG-seq and 
the mechanistic insight these applications can provide. 
 
5.2 VSG switching in vitro 
VSG-seq can be used to assess switching outcomes for experiments performed in 
culture. Recently, a MACS protocol49 in which parasites are coated in anti-VSG magnetic 
beads has been used for isolating populations of switched parasites in vitro. The antibody 
used is typically against the dominant or starting VSG in a population, retaining parasites 
expressing this VSG on the magnetic column while switched parasites are collected in the 
flow-through. The best way to measure switching outcomes in the isolated switcher 
population, however, has been through the laborious process of cloning individual 
switched cells, followed by sequencing of VSG cDNA isolated from each clone. In 
collaboration with Galadriel Hovel-Miner, I tested VSG-seq for measuring outcomes in 
an experimental switch population as part of a project investigating the role of 70-bp 
repeats in antigenic variation in T. brucei.  
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Earlier work from several labs had led to the hypothesis that 70-bp repeats play a 
role in antigenic variation. This prevailing, but unproven, hypothesis speculated that these 
repeats provided recombinatorial homology that facilitated the "choosing" of a VSG 
donor sequence in switching35-38. My collaborator had already determined, using a 
number of mutant parasite lines, that this repeat sequence, adjacent to most VSGs, indeed 
plays a role in selection of non-BES VSGs during a VSG switch. She found that mutants 
lacking the 70-bp repeats at the active BES (Δ70) are restricted in their ability to access 
the entire repertoire and switch only to VSGs located at other telomeric BESs (Hovel-
Miner, et al, in submission). Additionally, this Δ70 mutant switched very frequently, at 
levels orders of magnitude higher than a wild type strain in vitro. She had determined that 
introduction of a minimal repeat, consisting of a 70-bp repeat dimer, reduced levels of 
switching to wild type levels, whereas a reversed dimer sequence at the active BES 
switched as frequently as a Δ70 mutant. The key experiment to demonstrate the role of 
this repeat with respect to VSG donor selection, however, needed to show that a dimer 
allowed access to the non-BES archive, while a reversed dimer sequence did not. 
Previously, this would have required additional rounds of laborious cloning and 
sequencing of individual VSGs after isolation of the switched population by MACS. 
VSG-seq enabled us to assess repertoire access by the two mutants in a faster, less 
biased, and higher-resolution way. I applied VSG-seq to switched populations isolated by 
MACS from biological triplicates of each line to determine the switching outcomes for 
each. I observed that the line lacking repeats in the active BES (Δ70) could occasionally 
select VSGs from sites other than BESs (Figure 5.1). This was in contrast to previous data 
using cloning to identify switching outcomes, which showed absolutely no selection from 
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sites other than BESs, and highlights the increased resolution of VSG-seq. Nevertheless, 
introduction of the repeat Dimer resulted in an increase in the number of VSGs selected 
when compared with the no-repeat line (average of 18 VSGs in Δ70-ISceI and 35 VSGs in 
Dimer). This increase in diversity of VSG selection appears to be due to an increase in 
selection of MC VSGs. The Δ70 strain selected 1 MC VSG, whereas the Dimer strain 
selected an average of 11 MC VSGs. There was an additional, albeit smaller, increase in 
the selection of VSGs arising from undermined loci. In contrast, the strain carrying a 
reversed dimer sequence did not result in a significant increase in the selected VSG 
repertoire. These data confirmed that two 70-bp repeats at the active BES are sufficient to 
allow selection of VSGs from non-BES sites, and that the 70-bp repeat sequence is 
required for this selection, as a reversed Dimer sequence prevents the selection of VSGs 
outside of BESs. Thus, VSG-seq can facilitate the quick profiling of switching outcomes 
towards an understanding of switching mechanisms in vitro. 
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Figure 5.1. VSG-seq analysis of 70-bp repeat mutant strains.  
Switching outcomes in populations of MACS-isolated switchers from three biological 
replicates of Δ70, Dimer, & Dimer Rv are shown in a heat map, where color intensity 
reflects the proportion of each VSG in the population. The Lister 427 VSG number and its 
predicted genomic location are shown on the right. “var” indicates that the assembled 
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5.3 Antigenic variation field isolates 
One of my primary goals in developing VSG-seq was to develop a method that 
could be applied to T. brucei field isolates. In collaboration with Veerle Lejon and Stijn 
Deborggraeve, I tested the feasibility of applying VSG-seq to samples collected from 
natural human infections. The samples analyzed were collected from parasitologically 
confirmed stage 1 or stage 2 HAT patients in the Democratic Republic of the Congo. 
RNA was extracted from 2.5 mL of blood from each patient. An estimate of 
parasitemia for each patient was made microscopically by examining the buffy coat of 
10ml of blood, and by QPCR134 on the isolated RNA.  QPCR was used to infer the 
relative parasitemia of samples and did not provide an absolute measure of parasitemia. 
All samples analyzed, except for one (RB0017S), showed >50 parasites microscopically. 
RB0017S showed 21-50 parasites in the isolated buffy coat, and its relatively lower 
parasitemia was confirmed by QPCR. Though sensitive for diagnosis, visual counting of 
parasites concentrated in the buffy coat is not particularly accurate for estimating 
parasitemia135, and these counts do not indicate a parasitemia of 5 parasites/mL. Rather, 
these results show that all patients analyzed presented with relatively high parasitemia for 
infection with T. b. gambiense.  
The VSG PCR step of the VSG-seq library preparation was somewhat inefficient 
in these samples, producing many nonspecific bands. This was probably due to the high 
level of host RNA present in each sample, relative to parasite RNA. To improve 
enrichment for VSG sequence, an alteration to the library preparation was made in which 
PCR products ranging in size from 1kb to 2kb were gel extracted and used as input 
material for creating sequencing libraries, rather than using all PCR products.  
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This approach appears to have worked, as VSG sequences were assembled from 
all five samples analyzed. Analysis parameters were difficult to set, however, due to the 
unknown parasitemia in each sample. To be conservative in my analysis, I only counted a 
VSG as present within the population if it was present at >1% of the population. In T. b. 
gambiense infection, parasitemia can be as low as <100 parasites/mL135, though this is 
unlikely given the estimates of parasitemia in these samples. If parasitemia were indeed 
<100 parasites/mL, a detection cutoff of 0.1% could result in significant overestimations 
of diversity.  
Using this relatively conservative cutoff, VSG diversity in each sample ranged 
from 2 to 7 VSGs (Figure 5.2A). Using a detection cutoff of 0.01%, which assumes at 
least 10,000 parasites per sample or 4,000 parasites/ mL of blood, diversity ranges from 7 
to 11 VSGs per sample. This is somewhat lower than observed in mouse infections but 
perhaps unsurprising, given the low parasitemia typical of T. b. gambiense infection, and 
the likelihood of pre-existing immunity against certain variants in these patients132.  
A comparison of expressed VSGs showed some overlap between samples (Figure 
5.2B). RB0011S and RB0030S contain the same two VSGs, and one VSG is in common 
between RB0011S, RB0017S, and RB0030S. Interestingly, there was no overlap between 
RB001S or RB002S and the other samples.   
It is important to consider the relationships between each sample when 
interpreting the overlap in expressed VSG repertoires. RB001S and RB002S came from 
the same village around the same time, while RB0011S and RB0017S were isolated 
around the same time in the same clinic. RB0030S was the outlier in this set, collected far 
from the other samples. With respect to time, all samples were collected within a one-
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month period. The overlap between VSG repertoires is interesting considering the 
relationships between these samples; those with the most in common are not necessarily 
those with any temporal or geographic relationship.  
Figure 5.2. VSG-seq analysis of human T. gambiense infections.  
(A) Pie charts showing VSG expression in each sample, using a 1% detection cutoff. 
Colors in each chart represent the same VSGs, with the exception of the chart for Patient 
RB001S (*), which was analyzed separately and has no VSGs in common with the other 
samples.  (B) Venn diagram showing overlap in VSG repertoire between patients 
RB002S-RB0030S. 
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Analysis of the identity of VSGs expressed in each sample also revealed 
something unusual: the most abundant VSG identified in patient RB0017S is identical to 
a common BES-associated Lister 427 VSG, VSG-11. Using less strict analysis 
parameters, this VSG also appears in RB002S (0.02%) and RB0030S (0.7%). No other 
common VSGs were identified in this analysis. The significant overlap in expressed VSG 
repertoires between these infections may provide hints at both the diversity of VSG 
repertoires between parasite subspecies as well as the extent of the expressed VSG 
repertoire in the wild. 
There is of course, a major caveat to these observations, which is that it is not yet 
clear whether using such small starting samples affects quantification. In these samples, 
the amount of parasite RNA is low, and host RNA is in significant excess. Control 
experiments, along with possible optimization of the method, will need to be performed 
to show that high levels of contaminating RNA do not affect quantification. Although 
more experiments are needed to shore up these findings, they suggest not only that VSG-
seq will work on samples isolated from natural infections, but also that there are 
interesting things to be found in wild T. brucei populations. The genomic repertoire has 
been compared between some species and subspecies of African trypanosome136,137 but 
not the expressed repertoire, which these data show may be distinct and important. 
5.4 Antigenic variation in extravascular parasite populations 
Finally, VSG-seq provides the opportunity to investigate parasites beyond those 
found in the bloodstream of the host. Even in the earliest days of T. brucei research, it 
had been recognized that parasites could be sequestered in specific tissue niches, the 
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central nervous system (CNS) in particular, where they could be protected from 
chemotherapy, to later re-enter the bloodstream and re-establish infection138,139. Although 
it had been thought that T. brucei existed primarily in the bloodstream until late in 
infection, when it invades the CNS and neuropathology appears in patients, recent work 
in mice shows that parasites invade extravascular sites throughout the body after only 6 
days of infection. In addition to the CNS, parasites can be found in the heart, lung, liver, 
spleen, and adipose tissue and, in all cases, parasites are found extracellularly in the 
interstitium of these tissues. Surprisingly, by day 28 p.i. this extravascular population 
represents the majority of parasites in the mouse (Luisa Figueiredo, in submission). 
Parasites residing in adipose tissue have been found to take advantage of novel metabolic 
pathways to utilize fat as a nutrient source, while CNS-resident parasites are 
morphologically different from the well-characterized bloodstream form T. brucei9. The 
unique properties of parasites residing in other tissues have not yet been characterized, 
but together these results suggest that the extravascular niche is not simply a side effect 
of high parasitemia at the late stages of infection, as once thought. Instead, it is likely that 
this niche is an important phase of the parasite’s lifecycle, one that has not yet been 
characterized with respect to antigenic variation.  
VSG-seq provides an opportunity to examine the expressed VSG repertoire within 
extravascular populations. With this in mind, in collaboration with Luisa Figueiredo, I 
performed a pilot experiment on samples collected from two mice infected with 
EATRO1125 T. brucei expressing the VSG AnTat1.1. One set of samples was collected 
from day 6 p.i. and the other from day 28. In both cases, blood was first collected, 
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followed by perfusion of the animal with PBS. RNA was isolated from blood and from 
brain, fat, heart, and lung. This material was used for VSG-seq.  
Analysis of these samples showed the number of VSGs expressed in each tissue 
did not correlate with the number of parasites present in that tissue (Figure 5.3A), though 
generally diversity was higher on day 28 than day 6, consistent with previous 
observations. The number of VSGs expressed in parasites in blood was somewhat higher 
than previously observed, but this was likely due to the fact that these infections were 
initiated with 5000 parasites, rather than only 5. It is possible, however, that this 
difference in diversity is the result of differences in the host mouse strain, as these 
experiments were performed in C57Bl/6 mice, rather than the Balb/c mice used in 
Chapter 3 and 4. 
Comparison of VSG populations in each tissue revealed a complex situation 
within the host. On both day 6 (Figure 5.3B) and day 28 (Figure 5.3C) VSGs could be 
found that were unique to an individual tissue. Some tissues seemed to contain more 
unique VSGs than others but, with only two infections, it is hard to interpret these data. 
Nonetheless, the high diversity across tissues can be taken as evidence that this is not 
well-mixed system; a simple survey of parasites in the blood is not representative of the 
tissue niche.   
	  





Figure 5.3. VSG expression in extravascular spaces.  
(A) Scatter plot showing the number of VSGs expressed in each tissue compared to the 
number of parasites in the sample analyzed. (B) Venn diagram showing overlap in 
expressed VSG repertoire between each tissue on day 6 post-infection. (C) Venn diagram 













































































Comparison of VSG populations in each tissue to those in the blood may hint at 
possible roles for this extravascular niche. VSG-seq analysis of perfused tissues on day 6 
p.i. showed that while nearly every VSG expressed in other tissues was also present in the 
blood, over half of the VSGs identified in the lung were unique to that space (Figure 5.4). 
Could the lung be a site for initiating VSG switching or diversification? While the 
situation on day 28 of infection was more complicated (Figure 5.4), there was one 
striking observation resulting from this comparison: while the initiating VSG (AnTat1.1) 
had been cleared from the blood and the heart, it persisted in the brain, fat, and lung. In 
fact, the initiating VSG was expressed in 1.4% of all parasites in the brain. Thus, certain 
extravascular spaces appear to be immune-privileged, which could be important for 
parasite dynamics in vivo. 
Figure 5.4. Overlap in VSG repertoire between extravascular spaces and blood. 
 (A) Venn diagrams showing the overlap in expressed VSGs between each tissue and 
blood on day 6 post-infection. (B) Venn diagrams showing the overlap in expressed VSGs 
between each tissue and blood on day 28 post-infection.  
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5.5 Discussion 
These experiments show that VSG-seq can be applied successfully to many types 
of samples, and in all cases has the potential to provide insight into the mechanisms of 
antigenic variation in T. brucei. My experiments examining the role of 70-bp repeats in 
VSG donor selection in antigenic variation confirmed previous observations, but provided 
much higher resolution than possible using previous approaches. Moreover, the method is 
much less laborious than other strategies for profiling switch repertoires.  
Studies of VSG repertoires in wild isolates provide evidence that this approach 
could be easily applied to any natural infection. Although some optimization and 
validation will be needed, the findings from this small experiment hint at interesting 
possibilities. VSGs known to be present in T. b. brucei were found in infections presumed 
to be T. b. gambiense. This could suggest co-infection, the transfer of genetic material 
between parasites6,7, or that the expressed VSG repertoire is, for some other reason, 
somewhat constrained. An understanding of the extent of and limitations on the wild VSG 
repertoire could affect our understanding of the epidemiology and molecular biology of 
this infection in the wild, as well as our approaches to treatment and prevention of 
African trypanosomiasis.  
Analysis of parasites in extravascular spaces in experimental mouse infections 
reveals a new aspect of T. brucei antigenic variation. Based on these data, is it clear that 
the population in the bloodstream of an animal is not representative of the entire parasite 
population in vivo. This could have significant implications for parasite biology. For 
example, the presence of many unique variants in the lung early in infection may imply a 
role for this site in antigenic variation. The persistence of certain variants after four 
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weeks of infection indicates an immune privileged niche in certain extravascular spaces 
that could serve as a refuge for switching in vivo. Taken together, the set of experiments 
described in this chapter demonstrates the promise of high-throughput methods for 
tackling many questions in the field of T. brucei antigenic variation.  
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CHAPTER 6. Discussion 
 
6.1 Development of VSG-seq 
An understanding of the dynamics of VSG expression and switching is an 
important step towards understanding the mechanisms driving immune evasion in T. 
brucei infection as well as the host response to VSG. For technical reasons, however, it 
has been challenging to measure VSG expression in vivo in a high-resolution way. Some 
have tried to address the question of VSG dynamics in other ways, either by mathematical 
modeling5,78,81,82,84,85 or by using low-throughput approaches47,64,79,80,87,88. While our 
understanding of the genomic VSG repertoire has improved greatly in recent years due to 
next-generation sequencing approaches, our understanding of how that repertoire is 
accessed in vivo has not yet benefitted from more modern techniques. 
To address this gap in our understanding of VSG switching, I developed a next-
generation sequencing approach, termed VSG-seq, for measuring VSG expression in high 
resolution. Based on de novo assembly, the method obviates the requirement for a 
reference genome, and allows for the identification and quantification of VSG expression 
from any strain of T. brucei. The method, orders of magnitude higher in resolution than 
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6.2 Confirmation of existing hypotheses 
Using VSG-seq, I profiled VSG expression in both acute and chronic mouse 
infections. My results confirmed many predictions made based on low-throughput 
studies. Indeed, the predictions made by Hall, et al.64, of an average of 32 and as many as 
95 VSGs at any time were extremely accurate: I measured an average of 28 and as many 
as 83 VSGs expressed as one time. It is telling that these estimates are somewhat higher 
than my measurements, as the limit of detection of VSG-seq prevents the method from 
sampling every VSG in a population. Moreover, recent work on samples collected from 
sleeping sickness patients92 along with my own results from sequencing patient samples 
suggest that this VSG diversity is not simply an artifact of the mouse model and may be 
clinically relevant.  
In line with predictions of a hierarchy in VSG switching, I observed that VSG 
populations in chronic infections were distinct at different stages of infection and that 
there was a clear preference for expression of certain VSGs during the first 30 days of 
infection. Additionally, my work again confirmed the observation that mosaic VSGs 
dominate only after the first peaks of infection, as I was only able to detect these variants 
on day 18 p.i. or later.  
These support previous predictions and lay the foundation for a more in-depth 
study of switching hierarchy and order. Because the chronic infections in this study were 
each initiated with a different VSG, explicit questions of order could not be addressed. I 
hope to address these questions explicitly in the near future, however, by initiating sets of 
infections with specific VSGs and comparing the switching outcomes. This of course will 
require the generation of a good catalogue of BES-associated and genomic VSGs in the 
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EATRO1125 strain. Once generated, such a catalogue can be used to assess the 
relationship between VSG order and genomic position. Are the same set of VSGs 
switched to no matter what VSG begins an infection, consistent with a model in which 
only genomic location matters, or is preference relative to the starting VSG, supporting a 
model in which homology in or around the expressed VSG plays a larger role? This 
experiment should determine whether hierarchy is independent of initiating VSG, as the 
experiment described in Chapter 4, comparing infections beginning with different 
variants, suggests.  
 
6.3 New questions about antigenic variation: Minor variants 
In addition to lending to support to existing hypotheses, my work brought to light 
aspects of infection that could not have been accessed using other approaches. During 
infection, many VSGs are expressed at a single time, but most of these variants never 
establish to levels at which they could have been detected using low-resolution 
techniques. The presence of these minor variants both supports the hypothesis that 
immune cross-reactivity plays a role in determining variant order during infection85,86, as 
well as the concept that the complete VSG repertoire (~400 VSGs in Lister 427, ~500 in 
EATRO1125) is insufficient to support the long T. brucei infections observed in the field. 
Many of those 400-500 variants fail too quickly to contribute significantly to immune 
evasion. Thus, VSG diversification through the formation of mosaic VSGs or other yet-to-
be identified mechanisms may play a more significant role in sustaining infection than 
previously appreciated. 
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 Perhaps most interestingly, the identification of minor variants raises a new 
question relevant to understanding VSG expression dynamics: what determines variant 
fitness? My data suggest that fitness is not solely intrinsic to the VSG. Although I have 
proposed antibody cross-reactivity or the individual host’s unique germ line B cell 
repertoire to be factors that determine variant success or failure, this has certainly not 
been proven. To address this hypothesis, one could examine, for example, the likelihood 
of an individual variant to be minor after the expression of an antigenically similar VSG 
during the same infection. If the host immune system is primed to recognize a variant 
because an earlier VSG was antigenically similar, that variant should not establish in the 
population as successfully as the previously expressed VSG. Addressing this 
experimentally would require an understanding of antigenic "classes" of VSG based on 
the ability of VSGs that are different in primary sequence to elicit similar antibody 
responses. There are only two VSG crystal structures, however, so it is difficult to predict 
which variants are likely to be similar at the structural level based on sequence alone. 
Currently, little is known about how antibody binds VSG, but patterns of VSG success 
and failure in vivo might inform our understanding of the antibody-VSG interaction. 
Perhaps pairs of variants in which one frequently “fails” when expressed during the same 
infection as the other are in fact structurally and antigenically similar. 
  
6.4 New questions about antigenic variation: The wild VSG repertoire 
The identification of minor variants in the bloodstream during infection raised 
new questions about the biology of antigenic variation in T. brucei, but the application of 
VSG-seq to patient samples and extravascular parasites raised even more. The study of 
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field isolates presented in Chapter 5, although quite preliminary, has potentially 
interesting implications for the wild VSG repertoire. The expressed repertoire of VSGs in 
the field could be important for understanding both parasite ecology as well as host 
immunity. My data show significant overlap in expressed VSG repertoires between 
geographically distinct infections. Does this mean the expressed VSG repertoire in the 
field is actually quite limited? If so, what restricts the repertoire to such a degree? Could 
host immunity play a role in the detectable expressed VSG repertoire?  
Additionally, my data show one VSG that is expressed in at least one patient, and 
possibly three, which is BES-associated in the Lister 427 strain of T. b. brucei. This again 
suggests a limited VSG repertoire, but in this case across T. brucei subspecies. Does this 
reflect a shared ancestral VSG repertoire, sexual recombination between parasite 
subspecies in the tsetse, or coinfection?  
 Perhaps this limited repertoire is unsurprising. One of the most common HAT 
field diagnostics is the card agglutination test for trypanosomiasis (CATT) 135,140,141, 
which diagnoses patients based on the presence of antisera against a three VSGs 
commonly expressed by parasites in West Africa. Thus, the repertoire regionally appears 
to be constrained enough to use the presence of an anti-VSG antibody response for 
diagnosis. Interestingly, however, these variants do not predominate throughout Africa, 
and one study showed the absence of the gene encoding one of these variants in some 
trypanosome strains isolated in Cameroon142. Thus, an understanding of the wild 
expressed VSG repertoire and how it changes in different regions could lead to the 
development of diagnostics specific for different regions in Africa. Although these data 
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are quite preliminary, they suggest there is interesting biology happening in natural T. 
brucei infections that will be worth investigating in the future. 
Another source of interesting biology in natural VSGs repertoires is in the tsetse 
salivary glands. Because only hundreds of metacyclic parasites need to be injected by the 
tsetse for transmission143, and these parasites initiate nearly all infection, could there be a 
limited inoculating repertoire? Studies of the genomic set of metacyclic VSGs show only 
between 5 and 27 metacyclic VSGs in the genome26,144, and another study shows some 
evidence that metacyclic VSGs are less likely to rearrange to form mosaic variants, 
further limiting this repertoire145. How extensive is the wild metacyclic expressed VSG 
repertoire? If the repertoire is in fact limited, this could have dramatic consequences for 
therapeutic approaches for HAT, including vaccination.  
 
6.5 New questions about antigenic variation: Extravascular parasites 
The study of parasites residing in extravascular spaces in tissues described later in 
Chapter 6, though once again very preliminary, has significant implications for our 
understanding of antigenic variation in vivo. A surprising number of VSGs are expressed 
exclusively in the lung. This suggests that the lung may be a site of early switching and 
diversification. If this is the case, it may indicate the existence of a trigger for switching 
or diversification unique to that tissue. One such trigger could be oxygen tension, which 
is higher in the lung than in other tissues146, and which is known to affect the expression 
of a major surface glycoprotein in procyclic forms of the parasite147. Such a hypothesis 
could be tested easily by varying oxygen concentrations in parasite cultures and 
measuring the effect on antigenic variation. Of course other factors, such as pH, could 
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also serve as a trigger for switching. So far, there is no known environmental factor that 
can initiate VSG switching, but these data suggest that one might exist.  
An alternative explanation for the increased diversity in the lung is the lack of an 
antibody response within that tissue, which would preclude specific clearance of any 
variants and allow parasites expressing antigenically similar VSGs to survive and grow. 
The persistence of early expressed VSGs in certain spaces (brain, fat, and lung) long after 
they have been cleared from the blood supports a model in which increased VSG diversity 
results from immune-privileged sites in the host. This observation, once confirmed, could 
be followed up by a study of the B cell populations and antibody repertoires, both general 
and VSG-specific, within each potentially immune privileged tissue. Such experiments 
might reveal certain antibody isotypes that are present or absent from each site. For 
example, although IgM is thought to be the primary isotype involved in parasite 
clearance96, the role of IgM and other isotypes in the context of extravascular spaces is 
not known. Thus, it is possible that IgM is required for parasite clearance in tissues and 
that early variants persist in certain spaces because the bulky IgM molecule cannot 
diffuse efficiently into those spaces. On the other hand, if VSG-specific antibody or B 
cells can be detected but parasites expressing that VSG have not been cleared, it may be 
that T. brucei modulates the host B cell response in these spaces. Very little is known 
about immune privilege or the extravascular B cell response, but sequencing of the 
expressed extravascular VSG repertoire may have indirectly shed light on both of these 
phenomena. 
Moreover, it might be possible to take advantage of immune-privileged spaces, if 
they exist, experimentally. Due to antibody cross-reactivity, it is likely that many variants 
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never establish in the bloodstream. This may be especially true for mosaic VSGs, which 
are more likely to be antigenically similar to a previously expressed VSG, particularly if 
they do form in the active BES. The early clearance of cross-reactive or less fit variants 
in the blood leads to a skewed view of the VSG population in vivo. Immune-privileged 
spaces may provide a better context for studying the mechanisms of switching and VSG 
diversification, as all variants would be detected in such sites.  
The application of VSG-seq to tissue-resident parasites has hinted at two potential 
roles for these spaces. In addition to this, a more extensive study of parasite populations 
over time in each space could provide information on the presence of variants in each 
niche over time.  This kind of data could then be used to create a map of T. brucei’s route 
through the tissues of its host, something about which very little is currently known. 
Another major unanswered question that would be informed by an extension of these 
experiments is whether VSGs have a role in sequestration of trypanosomes in different 
physiological niches, as is the case for the var gene family in P. falciparum infection148. 
Could certain VSGs be lung- or brain-specific? 
 
6.6 New answers to old questions: Mosaic VSGs 
Although many aspects of antigenic variation are informed by this work, nearly 
every finding in these investigations points towards one theme: VSG diversification. The 
set of expressed VSGs at any given time during is large. Of those many variants, half are 
destined to fail. An examination of the parasites in tissues reveals another layer of 
diversity. Over and over, it becomes clear that the genomic VSG repertoire alone is 
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insufficient to sustain an infection, and the parasite must diversify its VSG repertoire 
through the formation of mosaic VSGs. 
The idea that VSG diversification is critical to sustaining a chronic T. brucei 
infection is certainly not a new one88. Despite the obvious importance of the process, the 
mechanisms of VSG diversification in general, and mosaic VSG formation in particular, 
have remained elusive and experimentally intractable. VSG-seq, then, presents a new 
avenue for tackling this historically difficult question. My investigation of chronic 
infections revealed the first temporal data on the formation mosaic VSGs, suggesting that 
these novel variants form within the active expression site. The patterns of mosaic 
formation suggested by my data also raise interesting questions about the immune 
response to VSG. What use could mosaic formation in the buried C-terminal end of the 
VSG serve? It will be interesting to investigate whether mutations in the 3ʹ of the VSG 
can ever confer resistance to host antibody. The mosaics identified by VSG-seq may be 
ideal candidates for such analysis, because they are present at relatively high levels and 
should, to some degree, be capable of evading host antibody. Thus, the mosaics 
detectable by this method may be not only the variants most relevant to a natural 
infection, but also the variants most likely to confer an antigenic advantage in vivo. Thus, 
beyond informing antigenic variation in T. brucei, they may provide insight into the 
antibody-VSG interaction. 
Taken together, my results show that VSG-seq is not only descriptive. Instead, 
this approach can provide mechanistic insight into antigenic variation and the creation of 
mosaic VSGs. This high-resolution and quantitative technology can now be used to ask 
not only whether mosaic VSGs form, but when, where, and how. There is also no reason 
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why this approach cannot be applied to other systems, so questions of repertoire 
diversification can extend beyond the African trypanosome. Using VSG-seq, I have 
shown that high-throughput bioinformatics approaches are key to achieving the high-
resolution picture of VSG switching needed to understand the mechanisms of antigenic 
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CHAPTER 7. Methods 
 
7.1 Cell Culture 
 Control libraries (Chapter 2) were made using mixtures of Lister 427 clones each 
expressing a different VSG. Each line has an antibiotic resistance marker at the promoter 
of the active expression site and was grown in vitro in HMI-9 with antibiotic selection to 
minimize in situ switching. To make the libraries, parasites were counted with a 
hemacytometer and mixed in known proportions. RNA was isolated from these mixtures 
immediately and used for the preparation of VSG-seq libraries. 
 
7.2 Infections  
 For infections investigating parasite diversity in blood, female Balb/cByJ 
(Jackson Labs) mice were infected intraperitoneally with ~5 parasites (pleomorphic or 
monomorphic), and parasitemia was counted every 2 days by hemacytometer. 50–100 µl 
blood was collected by submandibular bleed for the isolation of parasites and preparation 
of sequencing libraries. Mice were sacrificed when they began displaying pathological 
symptoms. 
 For infections investigating parasite diversity in tissues, 6-10 week old male 
C57BL/6J mice (Charles River, France) were infected intraperitoneally with 2000 T. 
brucei EATRO1125 parasites.  Parasitemia was tracked daily by hemacytometer and 
animals were sacrificed on either day 6 or day 28 by CO2 narcosis.  
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7.3 Isolation of parasites from blood 
 Serum was removed from blood samples and saved, and the remaining material 
was incubated with Ter-119 microbeads (Miltenyi). Samples were then washed twice in 
HMI-9 and applied to a MACS column.  The flow-through was collected and these red-
blood-cell-depleted samples were divided for DNA (10%) and RNA (90%) isolation. 
DNA was isolated from a portion of the parasite sample using DNAzol (Invitrogen), 
according to the manufacturer’s protocol.  
 
7.4 Isolation of tissue-resident parasites 
For experiments examining tissue-resident parasites, mice were immediately 
perfused transcardially following euthanasia with pre-warmed heparinized saline using a 
peristaltic pump. Approximately 30 mg of each organ was collected into Trizol (Life 
Technologies). 
 
7.5 RNA isolation 
 For all experiments except for the investigation of parasites in human infections 
and in mouse tissues, RNA was isolated using RNA STAT-60 (Tel-Test, Inc.), according 
to the manufacturer’s protocol. 
For experiments examining tissue-resident parasites, RNA was isolated from 
perfused tissue samples with Trizol (Life Technologies) according to manufacturer’s 
instructions. Blood was isolated before perfusion and RNA was isolated from blood 
samples using Trizol LS (Life Technologies). 
 For human infection samples, samples were collected from parasitologically 
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confirmed stage 1 or stage 2 HAT patients in D.R. Congo. 2.5 ml of blood was collected 
in PAXgene tubes (Qiagen) in the field, which were shipped and stored at -80°C. RNA 
was extracted using a PAXgene Blood RNA Kit (Qiagen). 
 
7.6 VSG-seq Library Preparations for optimization 
Four approaches to VSG-seq library preparation were tested, each with slight 
variations in the protocol up until the production of fragmented dscDNA. Sequencing 
libraries were prepared from this fragmented material using the Illumina TruSeq DNA 
Sample Prep Kit v1 (FC-121-1001) according to manufacturer’s instructions. All libraries 
were sequenced on an Illumina HiSeq 2000 producing 100bp single-end reads. 
 
Prep 1: “VSG” 
For this prep, RNA samples were DNase treated using RQ1 RNase-Free DNase 
(Promega). After DNase treatment, samples were cleaned by phenol/chloroform 
extraction, and polyA mRNA was isolated using Sera-mag oligo(dT) beads, followed by 
first strand synthesis with SuperScriptIII Reverse Transcriptase (Invitrogen) using the 
VSG 3’UTR primer (see primers). Double-stranded cDNA was produced by combining 
10X Second Strand synthesis Buffer (NEB), 10mM dNTPs (NEB), E. coli DNA Ligase 
(NEB), E. coli DNA polymerase (NEB), and RNase H (Invitrogen) for 2.5 hours at 16ºC. 
After dscDNA was produced, DNA was fragmented to about 200bp using NEBNext 
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Prep 2: “oligo-dT” 
This prep, which sequenced all polyA mRNA, rather than just VSG mRNA, was 
performed exactly as the “VSG” prep, except that mRNA was chemically fragmented (4 
minutes at 94ºC in 30 mM Mg2+) to ~200nt and precipitated, and first-strand was 
performed using random hexamers. cDNA was not fragmented with dsDNA fragmentase 
after second-strand synthesis. 
 
Prep 3: “VSG + SL 2nd Strand” 
This protocol was performed as the “VSG” preparation above except, in place of the 
second-strand synthesis step, 2 cycles of PCR were performed, using Phusion polymerase 
(New England Biolabs) and the SL and SP6-14mer primers (see primers), to specifically 
produce double-stranded VSG cDNA.  
 
Prep 4: “Amplicon” 
This sequencing preparation was identical to the “VSG + SL 2nd Strand” preparation, 
except 30 cycles of PCR, rather than 2 cycles, were performed.  
 
7.7 Optimized VSG-seq library preparation 
 RNA samples were DNase treated using RQ1 RNase-Free DNase (Promega). 
After DNase treatment, samples were cleaned by phenol/chloroform extraction or using 
AMPure RNAClean XP beads (Agencourt), and first strand synthesis was performed 
using SuperScript III Reverse Transcriptase (Life Technologies), using a primer specific 
for the conserved 14-mer in the VSG 3´-UTR (see primers, all-VSG-3´-UTR).  1st strand 
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products were cleaned up using AmPureXP beads (Agencourt). 22 cycles of PCR (or 35 
cycles in the case of human infection samples), using Phusion polymerase (New England 
Biolabs), was performed to amplify VSG cDNA, using SL and SP6-14mer primers (see 
primers). PCR products were cleaned using AmPureXP beads and DNA concentration 
was measured using a QuBit HS DNA kit (Life Technologies), according to 
manufacturer’s protocol. Libraries were prepared from VSG PCR products using the 
Nextera XT DNA Sample Prep Kit (Illumina), according to the manufacturer’s protocol.  
 For control libraries in Chapter 2 and acute and chronic infections described in 
Chapters 2 and 3, 100bp single-end sequencing was performed on an Illumina HiSeq 
2000. For libraries described in Chapter 5, made from tissue samples, parasites isolated 
from in vitro cultures, and human infection samples, 150bp single-end sequencing was 
performed on an Illumina NextSeq 500. For human infection samples described in 
Chapter 5, libraries were prepared with one alteration to the protocol described above. 
Because of the amount of contaminating host RNA and very low parasitemia, PCR 
products between 1-1.5 kb were isolated by gel extraction using a QiaQuick Gel 
Extraction kit (Qiagen), after the amplification of VSG cDNA. 150bp paired-end 
sequencing was performed on these libraries by an Illumina MiSeq (for sample RB001S) 
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7.8 VSG-seq Analysis 
 Adapters were trimmed using trim_galore(v0.3.3) and SP6 sequences (from VSG 
PCR step) were trimmed using cutadapt(v1.3)149. 
 Because many VSGs show stretches of homology, quantification of expression 
can be complicated, whether allowing unique or multiply mapping reads during 
alignment. To address this issue, I used MULTo (v1.0) to create a mappability file for 
each reference genome120. Sequencing reads were aligned to the reference genome (either 
assembled or the Lister 427 VSGnome reference at http://129.85.245.250/index.html), 
using bowtie (v1.0.0)150 allowing only uniquely mapping reads and no more than two 
mismatches per read (-v 2 –m 1). Then, MULTo’s rpkmforgenes.py was used to calculate 
the FPKM value for each VSG. The percent of the population expressing each VSG was 
calculated by dividing the FPKM for a VSG by the total FPKM. The number of parasites 
expressing a VSG was calculated by multiplying the total number of parasites by the 
percent of the population expressing that VSG. 
 When a reference VSGnome was assembled, sequencing reads were assembled 
using Trinity 116 using --normalize_reads. Once libraries were assembled, in-house 
scripts were used to identify contigs with an open reading frame (ORF) of >900bp (where 
an ORF is identified as start codon to stop codon, or start codon to end of contig). These 
ORFs were then compared against the Lister 427 reference VSGnome 
(http://129.85.245.250/index.html) using BLASTn (v2.2.28+), and ORFs with an 
alignment with an e-value < 1e-10 were considered VSGs. These ORF sequences were 
then merged using cd-hit-est (cd-hit v4.6.1)151,152 with the following parameters: -c 0.9 -n 
8 -r 1 -G 1 -g 1 -b 20 -s 0.0 -aL 0.0 -aS 0.5.   
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 These potential VSG sequences were then evaluated by hand using NCBI’s 
BLASTn nr/nt database. Sequences that matched chromosomal sequences or non-VSG 
genes were removed.  
 Because some VSG sequences were very similar, and the alignment program 
bowtie150 cannot distinguish VSGs >98% similar in sequence using the described 
alignment parameters, sequences were then merged again using cd-hit-est  (-c 0.98 -n 8 -r 
1 -G 1 -g 1 -b 20 -s 0.0 -aL 0.0 -aS 0.5). This final merged contig file represents the final 
reference genome for each experiment.  
For analysis of 70-bp repeat modified strains (Chapter 5), assembly and 
quantification was performed as described above, followed by a comparison to the Lister 
427 reference database: assembled VSG sequences, when compared to the most similar 
427 VSG, were identified as the 427 VSG when they had either 100% identity over >99% 
of the length of the assembled ORF or >99% identity over 100% of the assembled ORF.  
Otherwise, assembled VSGs were referred to as variants of the most similar Lister 427 
VSG. After identifying the corresponding 427 VSG, noise (VSGs measured below the 
limit of detection, 0.01%) and contamination (the starting VSG, 427-2) were removed. 
The relative abundance of each remaining expressed VSG was then calculated using its 
measured FPKM. These data were then used to create a heatmap using heatmap.2 from 
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7.8 Mosaic Identification 
 Candidate mosaics were identified by comparing VSG sequences to two 
independently assembled genomes for this strain, which were kindly provided by Keith 
Matthews and Isabel Roditi. Candidate mosaics were VSGs with <80% of their length 
aligning to any sequence in either genome, and expressed in only one infection at >0.1% 
of the population. Primers were designed around the likely region of recombination (see 
primers) and PCR was performed using HotStarTaq (Qiagen). Mosaic amplicons were 
cloned using a Topo-TA cloning kit (Invitrogen) and sequenced to confirm validation. 
 
7.9 Primer sequences 
 
Table 8.1. Primer Sequences. 
Table of all primer sequences used for library preparations and mosaic VSG validation. 
 
  
Primer Sequence (5´ 3´)
SL ACA GTT TCT GTA CTA TAT TG
SP6-VSG14mer GAT TTA GGT GAC ACT ATA GTG TTA AAA TAT ATC
All-VSG-3´UTR GTG TTA AAA TAT ATC
TbURA3F CGG CAG CAG TTC TCG AGT
TbURA3R TGG CGT GTA CCT TGA GGC
c5477_g4_i1_d24-F GGA ATC ACA TCG CGG TTC CCA AAG
c5477_g4_i1_d24-R CAA TTT TGC CAT CTG CCC CTC CTG
c754_g1_i2_d105-F CTT CGA GAC GAC ACC AAA AGC CAC
c754_g1_i2_d105-R GGC CGC AAA TGC AGA AGA AAC CAT TAG
370_g1_i1_d102-F GTA AAC TTG AAC CGG CGG TGG C
370_g1_i1_d102-R CAG AGC ACT TTT TGG CAT CGG AGT T
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